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ABSTRACT 
Many health maintenance organizations (HMOs) have implemented programs 
providing varying degrees of annual drug coverage for Medicare beneficiaries enrolled 
in their plans. Older adult plan members in an HMO operating in central 
Massachusetts were able to choose among 3 drug benefit options starting January 1, 
1994: full coverage for prescription drugs, a maximum of $1000/year in coverage, or 
no drug coverage. As such, cost containment policies have been shown to affect 
prescription drug use and other types of health service utilization. The unintended 
effects of this policy are important to consider. This research investigated the effects 
of type of drug benefit plan chosen on use of lipid lowering agents (LLA), a group of 
drugs of well documented benefit for both primary and secondary prevention of 
coronary heart disease (CHD), which continues to be a leading cause of death in the 
United States and worldwide. 
The objectives of this study were a) to describe LLA utilization during a one-
year period, for both prevalent and new users, and to compare this utilization with 
various patient characteristics including gender, age group, prescriber specialty, 
comorbidities (CHD, diabetes, hypertension), and choice of drug benefit plan option; 
b) to examine differences in persistence to LLAs among members of different drug 
benefit plans; c) to determine the effect of drug plan benefit option on the type of 
statin drugs, a class of LLAs, prescribed (expensive versus the less expensive statins). 
Analyses were performed using 2229 seniors who were continuously enrolled 
between July I , I 993 and June 30, 1996 and had a prescription for an LLA. Of these, 
1551 were studied to describe the LLA utilization during a one-year period (paperl), 
322 to examine persistence to LLA (paper2), and 484 to investigate the type of statin 
prescribed (paper3). 
Statins were the most widely prescribed group of LLAs among both prevalent 
(61.8%) and new (65.5%) users, and a very low rate of combination therapy was found 
in both prevalent (1.6%) and new (0.9%) users of LLAs. This may, in part, explain 
why many patients on LLAs do not reach their target cholesterol levels since 
combination therapy is more effective than monotherapy in lowering cholesterol 
levels. 
The type of drug benefit plan option did not affect choice among LLAs, but 
comorbidities, mainly CHO and diabetes, seem to be among the main factors that 
influenced drug selection, possibly through affecting lipid levels. Patients with CHO 
were more frequently prescribed statin monotherapy (p<0.000 l in prevalent use; p= 
0.0028 in new use) and combination therapy (p=0.0467 in prevalent use) and Jess 
frequently prescribed bile acid sequestrants (p<0.0001 for prevalent use). Diabetic 
patients more frequently used fibrates (p=0.0032 for prevalent use), less frequently 
used bile acid sequestrants (p=0.0007 for prevalent use; p=0.0329 for new use), and 
niacin (p=0.0336 in prevalent use) compared to nondiabetics. 
Other observed differences include: females were more frequently prescribed 
bile acid sequestrants compared to males (p=0.0213 for prevalent use; p=O.O 168 for 
new use), which could be a result of confounding by diabetes since the significant 
difference disappeared after restricting the analysis to diabetics or non-diabetics. 
Cardiologists prescribed bile acid sequestrants more frequently (p=0.0008 for new 
use) and prescribed fibrates less frequently (p=0.0092 for prevalent use) than 
internists, and finally patients aged 65-69 were less frequently prescribed a bile acid 
sequestrant compared to other age groups (p=0.0006 in prevalent use). 
The overall discontinuation rate for LLAs increased with time from 18.3% 
after 6 months of therapy, to 46.4% at 12 months, to 66.3% at 18 months. 
Statin users had better persistence than non-statin users in the bivariate 
(p=0.0004) and multivariate (HR=0.536; CI=0.375-0.766; p=0.0006) models. In the 
bivariate models, males had better persistence than females (p=0.0078), and CHD 
patients had better persistence than non-CHD patients (p=0.0424), but no significant 
differences with regard to gender or CHD existed after controlling for covariates in the 
multivariate model. No significant differences existed with plan type in the bivariate 
model (p=0.3121) or multivariate model (HR= 0.877; CI=0.610-1.260; p=0.4777). 
Other variables, diabetes, other medications ~3 , age ~70 , were not significantly 
associated with persistence as well. 
There was no significant association between the drug benefit plan option and 
statin type prescribed (OR=0.654; CI=0.376-1.139; p=0.1335) after controlling for 
potential confounders including gender, age ~70, comorbidities (CHD, diabetes, 
hypertension), and physician prescriber specialty. There were no significant 
associations with other predictor variables as well. 
In sum, research results generally indicate that the policy of drug benefit plan 
option initiated at the HMO among older adult members did not significantly 
influence the choice among or persistence to LLAs. 
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PREFACE 
This dissertation is organized using the manuscript format. Part 1 consists of 
three studies that form the main body of the dissertation. Part 2 contains the 
appendices, which provide details required by the University, but are not usually 
presented in a published paper. 
Part 1 includes the following manuscripts: 
Study 1: Drug benefit plans for elderly under managed care: A 
pharmacoepidemiologic assessment of lipid lowering medication use. 
Study 2: Persistence of lipid lowering therapy: Influence of drug benefit plan option 
on time to discontinuation. 
Study 3: Predictors of prescriber' s choice among three statins: Influence of drug 
benefit plan option. 
Part 2 includes the following appendices: 
Appendix A. Background and significance 
Appendix B. Details of the Methods 
Appendix C. Overview of major findings 
Appendix D. Kaplan-Meier Survival curves and Log-log Kaplan-Meier survival 
curves 
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PART I 
Part I includes the following manuscripts: 
Study I : Drug benefit plans for elderly under managed care: A 
pharmacoepidemiologic assessment of lipid-lowering medication use. 
Study 2: Persistence oflipid-lowering therapy: Influence of drug benefit plan option 
on time to discontinuation. 
Study 3: Predictors of prescriber' s choice among three statins: Influence of drug 
benefit plan option. 
I 
Drug benefit plans for the elderly under managed care: A 
pharmacoepidemiologic assessment of lipid-lowering medication use. 
ABSTRACT: 
Background High cholesterol is a major cause of Coronary Heart Disease (CHO). 
CHD is the leading cause of death in the United States. The beneficial effects of Lipid-
lowering Agents (LLA) have been widely demonstrated in both primary and 
secondary prevention, and the choice among different LLAs is left to the prescriber. 
Objective To describe LLA drug utilization patterns in a patient population of 
Medicare beneficiaries enrolled in managed care; and to determine if these patterns 
differ by patient characteristics including type of drug benefit plan option. 
Methods Descriptive cross-sectional study of 1551 older adult members of an 
HMO in central Massachusetts who were prescribed LLAs during a 12-moth period. 
Drug use was categorized into five major classes: statin monotherapy, bile acid 
sequestrant monotherapy, fibrate monotherapy, niacin monotherapy, and combination 
therapy. We compared this utilization with different patient characteristics, including 
gender, age group, prescriber specialty, comorbidities (CHD, diabetes, hypertension), 
and choice of drug benefit plan option. 
2 
Chi-square analyses were used to assess differences in frequencies of the drug 
regimens utilized with various patient characteristics. This was carried out for both 
new and prevalent users during the one- year period. 
Results Statin monotherapy was the most frequently prescribed LLA in both 
prevalent (61.8%) and new users (65.5%). Combination therapy was the least 
prescribed regimen among both prevalent (1.6%) and new users (0.9%). 
The type of drug benefit plan option was not significantly associated with 
any of the drug classes in prevalent or new users. 
In prevalent LLA use, patients with CHD used statin monotherapy (p<0.0001) 
and combination therapy (p=0.0467) more frequently, but used bile acid sequestrants 
less frequently(p<0.0001) compared to patients without CHD. Diabetic patients used 
fibrates more frequently (p=0.0032), and used bile acid sequestrants (p=0.0007) and 
niacin (p=0.0336) less frequently compared to non-diabetics. Females were more 
frequently prescribed bile acid sequestrants compared to males (p=0.0213), but this 
difference no longer existed when the analysis was restricted to diabetics or non-
diabetics only, indicating a confounding effect of diabetes. Cardiologists prescribed 
fibrates less frequently than internists and other specialties (p=0.0092), and patients 
aged 65-69 were less frequently prescribed a bile acid sequestrant compared to other 
age groups (p=0.0006). 
In new LLA use, patients with CHD more frequently used statin monotherapy 
(p=0.0028). Diabetic patients used bile acid sequestrants less frequently than non-
diabetics (p=0.0329). Females were more frequently prescribed bile acid sequestrants 
3 
compared to males (p=0.0168), a result that could be confounded by diabetes since the 
result no longer existed when we restricted the analysis to non-diabetics. The low 
number of new bile acid sequestrant users with diabetes prevented us from conducting 
a valid chi-square test among diabetics only. Finally, internal medicine physicians 
prescribed bile acid sequestrants less frequently than cardiologists and other 
specialties (p=0.0008). 
Conclusion Statins remain the most widely prescribed LLA . A very low rate of 
combination drug use was found, which can in part explain why many patients on 
LLAs do not reach their target cholesterol levels. This finding may perhaps help 
increase the use of combination therapy in the near future. The type of drug benefit 
plan option did not affect choice among LLAs, but comorbidities, mainly CHD and 
diabetes, seem to be among the main factors that influenced drug selection, possibly 
through affecting the lipid levels and lipid profile of these patients. 
4 
BACKGROUND 
High cholesterol, specifically elevated low-density lipoprotein cholesterol 
(LDL-C), is a major cause of CHD [ 1-4], a link that was first made by the 
Framingham Heart Study [5]. Despite marked declines in mortality during this century 
[6-8] , CHO continues to be the leading cause of death among the US population [9-
11], and worldwide (10, 12]. Cardiovascular disease accounts for 950,000 deaths 
annually in the US including 460,000 from CHD (9]. In 1990, there were 489, 171 
deaths attributed to CHD [6], and 675,000 patients were discharged from US hospitals 
with a primary diagnosis of myocardial infarction (13]. Hospitalization for CHO 
continues to increase [7]. The prevalence of nonfatal CHD among US adults aged 40 
and above is reported to be 11.8% (11]. It remains an important disease with 
significant burden. Estimated yearly costs of CHD for medical treatment and lost 
wages in the US range between $50 and $100 billion (2, 9, 14]. 
Twenty-eight percent of US adults over age 20 have hyperlipidemia that 
warrants treatment (15] , based on the National Health and Nutrition Examination 
Survey (NHANES) III phase 2 data (collected from 1991-1994) and the 1993 National 
Cholesterol Education Program (NCEP) recommendations that were available at the 
time of the survey [2]. Since then, the guidelines have been updated in year 2001 [3], 
but our data coincides with the earlier guidelines [2]. 
Currently, the American Heart Association estimates that 70 million adults in 
the US have total cholesterol levels>200mg/dl, and that at least 40% of these 
individuals have cholesterol levels in excess of240mg/dl [9,16]. 
5 
Individuals aged 65 years and older constitute 12% of the US population [17, 
18] yet they consume approximately 30% of the prescribed medications [I 7-19]. By 
the year 2015, it is estimated that there will be over 45 million individuals aged 65 or 
older, representing a 31 % increase in this age group compared to the 2000 US Census 
[20]. The aging population, increased prevalence of diabetes and hypertension, and 
growing number of overweight Americans can explain the persistence of CHD as the 
leading cause of death [4]. Eighty-five percent of those who die from CHD are 65 
years of age or older [9]. Therefore, CHO-related research in this rapidly growing age 
group is of extreme importance. 
Currently, there are 4 major classes of LLAs in use: statins, bile-acid-binding 
resins, nicotinic acid, and fibrates [10]. Some of these drugs are also used to treat low 
high-density lipoproteins (HDL) as well [2, 3] . For convenience, the term LLA will be 
used to denote these drugs, as the majority of patients receive them for cholesterol 
lowering. The number of adults eligible for lipid-modifying therapy was recently 
increased in the NCEP Adult Treatment Panel (ATP) III guidelines [3] to more than 
65 million [16], many of whom will require drug therapy to achieve target cholesterol 
levels goals [21]. 
Statin drugs have assumed a major role in the treatment of LDL-C elevations. 
They are reversible inhibitors of HMG-CoA reductase. By inhibiting the rate-limiting 
step in cholesterol biosynthesis, these drugs reduce intracellular cholesterol stores. 
Increased numbers of LDL receptors are then generated, thereby restoring intracellular 
cholesterol homeostasis and accelerating clearance of LDL-C from the plasma [22, 
23]. 
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The beneficial effect of using these drugs is well documented through five 
landmark trials showing reductions in cardiovascular events in a diversity of patient 
populations, representing the continuum of individuals at risk for CHD (24] . The 
Scandinavian Simvastatin Survival Study ( 4S) (25] demonstrated improved survival 
and fewer cardiovascular events in hyperlipidemic CHD patients. The Cholesterol and 
Recurrent Events (CARE) (26] and the Long-term Intervention with Pravastatin in 
Ischemic Disease (LIPID) (27] extended the benefits to CHD patients with average 
cholesterol levels. In patients without CHD, evidence of benefit is provided by high 
risk primary prevention in men without a history of myocardial infarction (Ml) who 
were treated with pravastatin and diet in the West of Scotland Coronary Prevention 
Study (WOSCOPS) (28]. In addition, the beneficial effects were further demonstrated 
in low and moderate risk primary prevention in men and women with below average 
high density lipoprotein cholesterol (HDL-C) levels treated with lovastatin and diet in 
the Air Force Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TEXCAPS) (29] that extended these benefits to a substantial portion of the 
population. 
Bile-acids-binding resins have been in clinical use for more than 30 years (30] 
and are now mainly utilized as adjuncts to statin therapy for patients for whom further 
lowering of cholesterol is indicated (10, 31 ]. They act by binding to bile acids in the 
intestine resulting in a compensatory increase in bile acid synthesis and an up-
regulation ofLDL-C receptors in hepatocytes (10, 30]. Available agents include 
cholestyramine and colestipol. They decrease LDL-C by I 0-20% in doses of 5-10 mg 
twice daily (10, 32, 33]. 
7 
Nicotinic acid is the oldest available LLA, used since the 1950s [30]. It acts by 
inhibiting mobilization of free fatty acids from peripheral tissues, thereby reducing 
hepatic synthesis of triglycerides (TG) and secretion of very-low-density-lipoproteins 
(VLDL) [IO]. It is the most powerful agent for elevating HDL-C [30], and is effective 
in lowering TGs; thus it is helpful in management of mixed dyslipidemia [30] . 
Treatment with monotherapy has been shown to reduce fatal and nonfatal MI in 
secondary prevention [34] and the 15-year mortality rate [35]. It has been proven most 
effective in preventing CHO when given in combination with other drugs like bile acid 
binding resins [10, 36, 37] or fibrates [10, 38]. 
Fibrates include clofibrate, gemfibrozil, and fenofibrate [10] . They resemble, 
in part, a short chain of fatty acids and increase the oxidation of fatty acids in the liver, 
causing a decreased secretion of TG-rich lipoproteins, and in the muscles causing an 
increase in the lipoprotein lipase activity and uptake of fatty acids [IO]. Fibrates are 
the most effective TG-lowering drugs [ 10,30, 31], causing 25-40% reduction in TG 
[ 1 O]. Treatment with gemfibrozil was shown to reduce the frequency of heart disease 
in a 5-year placebo controlled study of patients with high VLDL and LDL-C 
concentrations in the primary prevention Helsinki Heart Study [39], and in a 
secondary prevention trial in men with low serum HDL [40]. Treatment with 
clofibrate produced similar results as well [41] . They are also useful in increasing 
HDL-C [42]. 
A meta-analysis by Gould et al [ 1] reinforced our understanding of the 
beneficial effects of all LLAs. It showed that the reduction of CHD and total mortality 
by LLAs could be explained by their lipid-lowering ability, and this reduction appears 
8 
to be directly proportional to the degree to which they lower lipids. The declines in 
CHD mortality this century [6-8] can be partially explained by the improvement in 
treatments and secondary prevention of MI [7]. 
In deciding the most appropriate approach to lipid-lowering therapy, 
prescribers are encouraged to use clinical judgment [2, 3, 31 ]. Therefore, the choice 
among LLAs is left to the prescriber. Even though patient characteristics may 
influence the choice of a certain agent, the precriber' s preferences and experience can, 
to some extent, determine the type of drug prescribed. Furthermore, despite the 
availability of several studies assessing the lipid-lowering ability of various drug 
classes, the choice among various LLAs in a population of elderly patients has not 
been largely explored. 
We examined the LLAs prescribed during a one-year period among a group 
Medicare beneficiaries with high cholesterol levels and enrolled in managed care. We 
compared this utilization with various patient characteristics including gender, age 
group, prescriber specialty, comorbidities (CHD, diabetes, hypertension), and choice 
of drug benefit plan option. This was carried out for both new and prevalent users 
during the one-year period. We hypothesized that significant differences in the 
prescribed LLAs mainly exist with comorbidities and age, and not with other factors 
including gender, type of drug benefit plan, and prescriber specialty. This was based 
on the risk factors of the ATP II guidelines [2] that were the standard of practice at the 
time of this research. 
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METHODS 
Data Source and study population 
The study population consisted of older adult members (Medicare 
beneficiaries) of a Health Maintenance Organization (HMO) operating in central 
Massachusetts, who were continuously enrolled in the plan during the period of July 1, 
1993 - June 30, 1996, and were prescribed an LLA. These members were able to 
choose among 3 drug benefit options starting January 1, 1994: full coverage for 
prescription drugs, a maximum of $1000/year in coverage, or no drug coverage. Those 
selecting full coverage paid an additional premium of $72.50/month ($870/year). 
Those with a $1000 maximum coverage paid an additional $39 .16/month 
($469.92/year). Those without coverage paid no additional premium. 
Information on demographic characteristics, drug benefit plan type, 
prescriptions, ambulatory visits, hospitalization, and diagnoses was available for this 
population cohort. The population study cohort was comprised of2229 members. We 
deleted 325 (14.6%) members who switched from the original plan chosen on January 
1, 1994, since we were unable to explore the effects of the type of drug benefit in these 
individuals. Of those, 251 (77.2%) switched from the full coverage plan, 61 (18.8%) 
from the $1000 maximum plan, and 13 (4.0%) from the no coverage plan. The final 
plans chosen by these patients were the full coverage plan in 89 patients (27.4%), the 
$1000 maximum plan in 186 (57.2%), and the no coverage plan in 50 (15.4%). 
We then identified patients who had a prescription for an LLA during the one-
year period between July 1, 1995 and June 30, 1996. Of 1904 patients, 1551 (81.5%) 
met the criteria, and were considered prevalent users of LLAs during the time period. 
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The first prescription during this one-year was considered for further evaluation in our 
analysis. New users were then defined as patients who did not have a prescription for 
the LLA during the one-year prior to the study period, between July 1, 1994 through 
June 30, 1995. This definition of new users has been previously used [ 43 , 44]. Of 1551 
patients, 345 (22.2%) met the criteria. 
We determined the frequencies of the following regimens among both 
prevalent and new users: statins monotherapy, bile acid binding resins monotherapy, 
nicotinic acid monotherapy, fibrates monotherapy, and combination therapy of 2 or 
more LLAs. Combination therapy was defined as having prescriptions for 2 LLAs of 2 
classes in the first or second month, and again in the third and fourth month. This 
definition was used to avoid misclassifying switching from one type of LLA to 
another as combination therapy. 
For all patients we determined the gender, age, drug benefit plan type, 
physician prescriber specialty, and presence of comorbodities including CHD, diabetes 
and hypertension. Age was categorized into three groups: 65-69, 70-74, and 75 years 
or older, based on the frequency distribution of different age groups in this population 
cohort. The prescriber specialty was categorized as cardiology, internal medicine, or 
other. A patient was considered to have CHD if there was a CHD diagnosis (ICD-9 
code= 410-414) prior to the LLA prescription or during the one year prior to the study 
period. Patients with a diabetes diagnosis (ICD-9 code=250) prior to the LLA 
prescription or during the one-year prior to the study date were labeled as diabetics. 
Finally, patients with a hypertension diagnosis (ICD-9 code= 401-405) prior to the 
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LLA prescription or during the one year prior to the study date were regarded as 
having hypertension. 
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Statistical analysis 
Descriptive statistics were used to determine the frequency of each regimen 
prescribed, overall and stratified by gender, age categories, presence of co-morbidities 
(diabetes, hypertension, or CHD), physician prescriber type, and the type drug benefit 
plan option. 
Chi-square analyses were used to assess differences in frequencies of drug 
regimens utilized by gender, age group, type of drug benefit plan, prescriber specialty, 
and comorbidities categories. This was carried out separately for both prevalent and 
new users of various LLAs. 
Additional analyses 
A Chi-square test was conducted among diabetic and non-diabetic patients 
separately for prevalent and new bile acid sequestrant use by gender, as well as for 
prevalent bile acid sequestrant use by age group. 
This test was conducted in different age groups separately for prevalent and 
new bile acid sequestrant use by gender. 
Statistical analyses were performed using SAS for Windows version 8.01 with 
P<0.05 as the level of significance. 
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RESULTS 
Descriptive statistics 
A total of 15 51 patients were continuously enrolled between July 1, 1993 and 
June 30, 1996, and prescribed an LLA during the one-year period between July 1, 
1995 through June 30, 1996. The mean age of these patients was approximately 71 
years of age, with 686 (44.2%) between 65 and 69 years of age, 555 (35 .8%) between 
70 and 74 years of age, and 310 (20.0%) 75 years or older. There were more female 
patients (n=946; 61.0%) than males (n=605; 39.0%) in our study population. 
Most of these patients were covered by the full coverage drug benefit plan 
(n=l 108; 71.4%), nearly a quarter of them by the partial coverage plan (n=410; 
26.4%), and a small percentage by the no coverage drug benefit plan (n=33, 2.1 %). 
Internal medicine physicians accounted for most of the prescriptions dispensed to 
these patients (n=1234; 79.8%), cardiologists for approximately 5% (n=77), other 
specialties for approximately 15% of the prescriptions (n=235), while we could not 
determine the specialty of 5 (0.3%) prescribers. Approximately half (52.3%) of 
patients had a CHO diagnosis prior to the LLA prescription (n=81 l), 28.4% had a 
diabetes diagnosis prior to the prescription (n=44 l ), and most had a hypertension 
diagnosis prior to the prescription (n= l 244; 80.2%). This information is presented in 
Table 1. 
Out of 1551 prevalent users ofLLAs, 345 (22.2%) were found to be newly 
prescribed during the one-year study period. The mean age of these patients was 
approximately 71 years of age, with 139 (40.3%) between 65 and 69 years of age, 133 
(38.6%) between 70 and 74 years of age, and 73 (21.2%) 75 years or older. There 
14 
were slightly more female patients (n=187; 54.2%) than males (n=158; 45.8%) in this 
population. 
Approximately 62% of the patients were covered by the full coverage drug 
benefit plan (n=213; 61.7%), nearly a third of them by the partial coverage plan 
(n=l 10; 31.9%), and a small percentage by the no coverage drug benefit plan (n=22, 
6.4%). Internal medicine physicians accounted for most of the prescriptions given to 
these patients (n=260; 76.3%), cardiologists for 9.1 % of the prescriptions (n=31 ), 
other specialties for approximately 15% of the prescriptions (n=50; 14.7%), while we 
could not determine the specialty of 4 (1.2%) prescribers. 62.0% of patients had a 
CHD diagnosis prior the LLA prescription (n=214), approximately a third had a 
diabetes diagnosis prior to the prescription (n= l 16, 33.6%), and most had a 
hypertension diagnosis prior to the prescription (n=279; 80.9%). These data are 
presented in Table 2. 
Drug regimens prescribed 
Statin monotherapy was the most frequently prescribed LLA in both prevalent 
(n=959; 61.8%) and new users (n=226; 65.5%). The next most frequently prescribed 
LLA was the bile acid sequestrant monotherapy in both the prevalent users (n=230; 
14.8%) and new users (42; 12.2%). Among prevalent users fibrate monotherapy 
(n=205; 13.2%) and niacin monotherapy (n=132; 8.5%) were less common. This was 
also observed in new users, where niacin (n=39; 11.3%) and fibrates (n=35; 10.1 %) 
utilization was similar. Combination therapy was the least prescribed regimen among 
both prevalent (n=25; 1.6%) and new users (n=3; 0.9%). These statistics are presented 
in Table 3. 
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Stratification by patient characteristics 
Prevalent users 
Table 4a summarizes the frequencies of various medication regimens stratified 
by gender, age group, drug coverage plan, LLA prescriber specialty, CHD diagnosis 
prior to prescription, diabetes diagnosis prior to prescription, and hypertension 
diagnosis prior to prescription, among prevalent users of LLA. 
Among patients on statin monotherapy, those with a CHD diagnosis prior to 
the prescription were more frequently prescribed a statin compared to those without a 
CHD prior to the prescription (66.6% versus 56.6%, p<0.0001). No significant 
differences existed among statin users stratified by gender, age group, drug coverage 
plan, LLA prescriber specialty, diabetes diagnosis prior to prescription, and 
hypertension diagnosis prior to prescription. The probability values are summarized in 
Table 5a. 
Cardiologists less frequently prescribed a fibrate monotherapy regimen 
compared to internal medicine physicians or other specialties (2.6% versus 13.3% and 
16.2% respectively; p=0.0092). Patients with a diabetes diagnosis prior to the LLA 
prescription were more frequently prescribed a fibrate compared to those without a 
diabetes diagnosis prior to prescription (l 7.2%versus 11.6%; p=0.0032). No 
significant differences existed among fibrate users stratified by gender, age group, 
drug coverage plan, CHD diagnosis prior to prescription, and hypertension diagnosis 
prior to prescription. The probability values are summarized in Table 5b. 
Examining patients using bile acid sequestrant monotherapy, we found that 
females more frequently received a bile acid sequestarnt compared to males (16.5% 
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versus 12.2%; p=0.0213). When the analysis was conducted in different age groups 
separately, a significant difference still existed in age group 65-69 (p=O.O 145). When 
the analysis was conducted in diabetic patients and non-diabetic patients separately, a 
significant difference between genders was not observed (p=0.4846 for diabetics; 
p=0.6238 for non-diabetics). 
Patients in the 65-69 age group were less frequently prescribed a bile acid 
sequestrant compared to the 70-74 and above 75 age categories (10.9% versus 17.8 % 
and 18.1 % respectively; p=0.0006). This result was significant after conducting the 
analysis in non-diabetics only (p=0.0038), but was not significant in diabetics only 
(p=0.0710). Patients with a CHD diagnosis prior to prescription were less frequently 
prescribed a bile acid sequestrant compared to patients without a CHD diagnosis prior 
to the prescription (11.1 % versus 18.9%; p<0.0001 ). Finally, patients with a diabetes 
diagnosis prior to the prescription were less frequently prescribed a bile acid 
sequestrant compared to patients with no diabetes diagnosis (10.0% versus 16.8%; 
p=0.0007). No significant differences existed among bile aid users stratified by drug 
coverage plan, prescriber specialty, and hypertension diagnosis prior to prescription or 
not. The probability values are summarized in Table 5c. 
With patients prescribed niacin monotherapy, those with a diabetes diagnosis 
prior to the prescription were less frequently prescribed niacin compared to those 
without a diabetes diagnosis (6.1 % versus 9.5%; p=0.0336). No significant differences 
existed among prevalent niacin users stratified by gender, age group, drug coverage 
plan, LLA prescriber specialty, CHD diagnosis prior to prescription, and hypertension 
diagnosis prior to prescription. The probability values are summarized in Table 5d. 
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As for combination therapy users, patients with a CHD diagnosis prior to the 
prescription were more frequently prescribed combination therapy compared to those 
without a CHD diagnosis (2.2% versus 1.0%; p=0.0467). A chi-square test for 
prescriber specialty would not be valid because of low cell counts, thus we did not 
conduct it. No significant differences existed among combination prevalent users 
stratified by gender, age group, drug coverage plan, diabetes diagnosis prior to 
prescription, and hypertension diagnosis prior to prescription. The probability values 
are summarized in Table Se. 
New Users 
Table 4b summarizes the frequencies of various medication regimens stratified 
by gender, age group, drug coverage plan, LLA prescriber specialty, CHD diagnosis 
prior to prescription, diabetes diagnosis prior to prescription, and hypertension 
diagnosis prior to prescription, among new users of LLA. 
Among patients prescribed statin monotherapy, those with a CHD diagnosis 
prior to the prescription were more frequently prescribed a statin compared to those 
without a CHD prior to the prescription (71.S% versus SS.7%, p=0.0028). No 
significant differences existed among statin users stratified by gender, age group, drug 
coverage plan, LLA prescriber specialty, diabetes diagnosis prior to prescription, and 
hypertension diagnosis prior to prescription. The probability values are summarized in 
Table Sa. 
With fibrate monotherapy users, no significant differences existed when 
stratified by gender, age group, drug coverage plan, physician prescriber, CHD 
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diagnosis prior to prescription, diabetes diagnosis prior to prescription, and 
hypertension diagnosis prior to prescription. The probability values are summarized in 
Table 5b. 
Examining patients on bile acid sequestrant monotherapy, females more 
frequently received a bile acid sequestrant compared to males (16.0% versus 7.6%; 
p=0.0168). When the analysis was conducted in different age groups separately, a 
significant difference was observed in the 70-74 age group (p=00.0298), and we could 
not conduct a valid chi-square in the 75+ age group because of low cell counts. When 
the analysis was conducted in non-diabetic patients separately, a significant difference 
was not observed (p=0.3687). We did not conduct a chi-square test among diabetics 
because of low cell counts. 
Internal medicine physicians prescribed bile acids less frequently than 
cardiologists and other specialties (8.1 %% versus 22.6% and 24.00% respectively; 
p=0.0008.). 
Finally, patients with a diabetes diagnosis prior to the prescription were less 
frequently prescribed a bile acid sequestrant compared to patients with no diabetes 
diagnosis (6.9% versus 14.9%; p=0.0329). No significant differences existed among 
bile acid sequestrant users stratified by age group, drug coverage plan, CHD diagnosis 
prior to prescription, and hypertension diagnosis prior to prescription. The probability 
values are summarized in Table 5c. 
Among patients using niacin monotherapy, no significant differences existed 
when stratified by gender, age group, drug coverage plan, physician prescriber, CHD 
diagnosis prior to prescription, diabetes diagnosis prior to prescription, and 
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hypertension diagnosis prior to prescription. The probability values are summarized in 
Table 5d. 
There were only 3 new users for combination therapy, thus we were not able to 
conduct a valid chi-square test because of low cell counts. 
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DISCUSSION 
Insurance claims data are increasingly being used in pharmacoepidemiologic 
research. Automated databases have been used to assess prescribing patterns [45-47] , 
impact of policies [48] , and drug adherence [43 , 44, 49-52] . They provide a cost-
effective alternative to post-marketing clinical trials in a real world setting [53 , 54]. 
Such databases provide a good source for describing drug use in the population , and 
for comparing patterns of use in subpopulations. Furthermore, data from the same 
HMO used in this investigation has been successfully used in previous research [ 48, 
50] 
The study population of both prevalent and new users had a high prevalence of 
CHO (52.3% in prevalent users, 62.0% in new users), diabetes (28.4% in prevalent 
users, 33.6% in new users), and hypertension (80.2% in prevalent users, 80.9% in new 
users) compared to the reported prevalences in the general population [11 , 55, 56], 
which is understandable considering it is a population of older adults being treated for 
hypercholesterolemia. The fact that most patients also chose the full coverage benefit 
plan (71.4% in prevalent users, 61.7% in new users) can be explained by higher drug 
use in this age group compared to younger patients [17, 18]. 
Among all specialties, internists, family and general practice physicians, and 
cardiologists have been reported to be the most frequent prescribers of LLAs [57]. 
Family care physicians and general practice physicians are included in our others 
category. Another important specialty included in the others category is 
endocrinology, because of the increased risk of cardiovascular complications among 
diabetics [58]. 
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Internists are reported to have more patients on LLAs compared to 
cardiologists and family physicians [59, 60] , and general practice physicians are more 
likely to initiate therapy at a higher LDL-C compared to cardiologists and internists 
[61]. We found that most prescriptions (79.8% in prevalent users and 76.3% in new 
users) were written by internists, which is consistent with previous research [59, 60]. 
Frequency of drug regimens prescribed 
Statin drugs were the most prescribed regimen in this patient population 
among both prevalent (61.83=%) and new (65 .51 =%) users. Among different LLAs, 
statins have been shown to be the most widely prescribed [30, 31 , 60, 62, 63] . They 
are recommended as first line agents when drugs are indicated to achieve treatment 
goals [3, 31, 64, 65]. They are the most effective in LDL-C lowering, and the best 
tolerated among LLAs [30, 64, 65]. The use of statin as a proportion of LLAs in the 
US retail pharmacies increased from 47% in 1991 to 78% in 1997 [66] , and accounted 
for 70% of the LLA prescriptions in Finland in 1993. The market share of fi brate 
derivatives and nicotinic acid declined at the same period [60, 66]. The poor 
tolerability of other agents including bile acid sequestrants, nicotinic acid, and fibrates, 
limits adherence and explains the relative lower rates of these drugs in this patient 
population [31 ]. 
Combination therapy, on the other hand, was the least prescribed regimen 
among both prevalent (1.6%) and new (0.9%) users of LLAs, despite the fact that 
combination therapy is safe, effective, and well tolerated [21 , 67]. This is consistent 
with what has been reported in previous research; surveys show that only a few 
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patients are receiving combination therapy [21 ]. Hyperlipidemia is generally under-
treated, and less than 45% of patients who qualify for therapy receive it [68] . Only 
38% of those who receive therapy achieve their target LDL-C goals [69]. Elderly 
patients fail to receive indicated lipid-lowering medications as often as 80% of the 
time [70, 71] and even fewer achieve their target cholesterol levels [71 , 72] . The 
A TPII guidelines [2] recommend switching to another drug or a combination of two 
drugs ifLDL-C targets are not achieved. The combination of 2 low dose drugs can 
achieve lipid reductions that exceed those observed with high dose monotherapy [21 , 
73], since the combination employs two different classes with complimentary 
mechanisms of action to give an additive effect [21] or possibly a synergistic one [ 67]. 
Some combinations may prove to be better tolerated than high-dose monotherapy with 
statins, because they allow the reduction of the dose and a favorable side effect profile 
[21]. There could also be a cost benefit as well , since the combination may cost less 
than the high-dose monotherapy. The low rate of combination therapy observed can 
partly explain why so many patients fail to achieve their target cholesterol levels [71 , 
72], and thus are not getting the intended benefit of their therapy. 
We compared the frequency of drug regimen prescribed among various patient 
characteristics including gender; age group, prescriber specialty, comorbidities (CHD, 
diabetes, hypertension), and choice of drug benefit plan option. 
The type of drug benefit plan was not associated with any of the drug classes in 
prevalent or new users of LLAs. Therefore, it was not among the factors affecting the 
choice among various agents, consistent with what we had hypothesized. 
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Among patients receiving statin monotherapy, those with a CHD diagnosis 
prior to the prescription were more frequently prescribed a statin compared to those 
without a CHD diagnosis prior to the prescription in both prevalent (66.6% versus 
56.6%, p<0.0001) and new (71.5% versus 55.7%, p=0.0028) users. According to 
ATPII guidelines that were available at the time of this study [2], and the more recent 
ATPIII guidelines [3], CHD places patients in the high-risk group with a lower target 
LDL-C of 1 OOmg/dl. Statins are the most effective in LDL-C lowering, and the best 
tolerated among LLAs [30, 64 ], thus we would expect these drugs to be the most 
prescribed in this high-risk patient group. 
In prevalent patients prescribed fibrate monotherapy, those with a diabetes 
diagnosis prior to the LLA prescription were mote frequently prescribed a fibrate 
compared to those without a diabetes diagnosis prior to prescription ( 1 7 .2% versus 
11.6%; p=0.0032). Atherosclerosis accounts for more than 80% of all mortality caused 
by diabetes and for most hospitalizations necessitated by diabetic complications, and 
the cardiovascular risk of a diabetic patient is 2-3 fold higher than a non-diabetic 
individual [58]. Furthermore, the lipid profile of diabetics is generally different from a 
non-diabetic [58]. Approximately 90% of diabetic patients have type II diabetes [74] , 
and the lipid profile in these patients is characterized by elevated plasma triglycerides 
[58, 74, 75] and reduced HDL-C [74, 75], although the total cholesterol and LDL-C 
levels are similar to a non-diabetic [58]. 
Several studies in lipid modifying therapy have included sufficient numbers of 
type II diabetics to be able to conclude that, as in non-diabetics, treatment of lipid 
abnormalities reduces the risk of future coronary risk [27, 76-78]. Fibrates have been 
24 
shown to be effective in diabetic patients [27, 76-78], since they are the most effective 
triglyceride lowering drugs [10, 30, 31] , causing 25-40% reduction in triglycerides 
[10, 42] and are useful for increasing HDL-C [42] , consistent with the lipid profile of 
diabetics. When triglycerides are high, the A TPII [2] guidelines also recommend that 
the choice of drug is preferably one that lowers triglycerides. This could explain the 
increased used of fibrates in diabetics compared to non-diabetics. Among patients who 
were newly prescribed a fibrate, the trend was the same with more frequent fibrate use 
among diabetics (12. l %) compared to non-diabetics (9.2%). However, this did not 
reach statistical significance in our study, possibly because of the lower number of 
patients. 
Cardiologists less frequently prescribed a fibrate compared to internal 
medicine physicians or other specialties (2.6% versus 13.3% and 16.2% respectively; 
p=0.0092). A possible explanation for this could be the type of patients seen by these 
different specialties. Diabetics mainly visit endocrinologists, who are in the others 
category, or by internists, and not by cardiologists. 
For patients using bile acid sequestrant monotherapy, females more frequently 
received a bile acid sequestrant compared to males in both prevalent (16.5% versus 
12.2%; p=0.0213) and new (16.0% versus 7.6%; p=0.0168) users. We believed that 
this could be due to the confounding effect of other factors like diabetes, since a 
slightly higher prevalence of diabetes in men over 60 has been reported, even though 
the prevalence in men and women is similar in other age groups [56]. Bile acid 
sequestrants have a tendency to raise triglycerides; thus, they are useful for patients 
with high LDL-C and normal triglycerides [10]. The lipid profile in diabetic patient 
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profile is characterized by elevated plasma triglycerides [58, 74, 75]. Other possible 
explanations include increased body weight, since the percentage of men who are 
reported to be overweight (63%) is higher than the percentage women (55%) [79], and 
higher Body Mass Indices (BMI) have been associated with higher triglyceride levels 
[80], where bile acid sequestrants are avoided [58, 74, 75]; and age, since the onset of 
elevated cholesterol levels occurs in women and men at different ages and with 
different severity [63]. We explored the effects of age by restricting the analysis into 3 
different age groups, but a significant difference still existed in some age groups. 
When we restricted the analysis to diabetics only or non-diabetics only, the gender 
differences no longer existed, indicating a confounding effect of diabetes. We could 
not investigate the effects of body weight because of the unavailability of such 
infonnation in the dataset. 
Patients in the 65-69 age group were less frequently prescribed a bile acid 
sequestrant compared to the 70-74 and above 75 age categories (10.9% versus 17.8 % 
and 18. l % respectively; p=0.0006). We could not find an explanation for this; it could 
be related to the reported decreased prevalence of diabetes after the age of 7 5 [81] , but 
the significant difference still existed when restricting the analysis to non-diabetics. 
This result could be due to other factors, such as differences in the body weights of 
these patients, which we could not explore. This effect was not observed among the 
new users of these agents. 
Patients with a CHO diagnosis prior to prescription were less frequently 
prescribed a bile acid sequestrant compared to patients without a CHD diagnosis prior 
to the prescription among prevalent users (11.1 % versus 18.9%; p<0.0001), possibly 
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related to the their poor tolerability and inconvenient dosing that make adherence 
difficult [31]. Thus, more effective agents might be preferred in this high-risk group. 
The same trend was observed in new users, but did not reach statistical significance. 
Patients with a diabetes diagnosis prior to the prescription were less frequently 
prescribed a bile acid sequestrant compared to patients with no diabetes diagnosis in 
prevalent (10.0% versus 16.8%; p=0.0007) and new users (6.9% versus 14.9%; 
p=0.0329). This result was expected, since bile acid sequestrants are usually avoided 
in diabetics because of their tendency to raise triglycerides [ 1 O] , and the A TPII 
guidelines recommend that the choice of drug is preferably one that lowers 
triglycerides when they are high [2]. 
We could not explain why internal medicine physicians prescribed bile acids 
less frequently than cardiologists and other specialties in new users (8 .1 % versus 
22.6% and 24.0% respectively; p=0.0008). Our findings could be related to the type of 
patients seen by these physicians; diabetics are not usually seen by cardiologists, thus 
we would observe more prescriptions by this subspecialty. This effect was not 
observed in prevalent users. 
In members prevalently using a niacin monotherapy regimen, patients with a 
diabetes diagnosis prior to the prescription were less frequently prescribed niacin 
compared to those without a diabetes diagnosis (6.1 % versus 9.5%; p=0.0336). The 
same trend was observed but did not reach statistical significance in the new users. 
Niacin has a propensity to worsen the control of blood sugar [82, 83] and should be 
used in caution with diabetic patients [83] , thus the result is understandable. 
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As for prevalent combination therapy users, patients with a CHD diagnosis 
prior to the prescription were more frequently prescribed combination therapy 
compared to those without a CHD diagnosis (2.2% versus 1.0%; p=0.0467). This is to 
be expected, considering the 1 OOmg/dl target LDL-C set by the A TPII guidelines [2] 
that were the standard of practice at the time of this study, and ATPIII guidelines [3] 
for these high-risk patients. The ATPII guidelines [2] recommend switching to another 
drug or a combination of two drugs if LDL-C targets are not achieved after 3 months 
of therapy. They also state that most LLAs can be used in combination, but a statin 
plus fibrate (and possibly a statin plus nicotinic acid) carries an increased risk of 
myopathy. Combination therapy is generally safe, effective, well-tolerated, and can 
achieve lipid reductions that exceed those observed with high dose monotherapy, since 
the combination employs two different classes with complimentary mechanisms of 
action to give an additive effect [21]. The low rate of combination therapy in this 
patient population, however, is noted. 
LIMITATIONS 
Several limitations to this study can be described. Regarding the dataset used, 
patients may fill their prescriptions from pharmacies outside the HMO network and 
thus will not be captured. This, however, is unlikely, since the drugs were provided at 
discounted prices for patients in these pharmacies, and the assumption that patients fill 
most of prescriptions within the pharmacy system under study has been confirmed in 
one HMO and 2 Veterans Affairs (VA) Medical Centers [84]. One study that tried to 
assess medication use outside the central pharmacy of the VA through a questionnaire 
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found that 98.5% of patients reported using the central pharmacy as their only source 
of medication [51). Even though the unique characteristics of the population studied 
may somewhat limit generalizability of results, administrative databases provide a 
cost-effective alternative to post marketing clinical trials in a real world setting [53, 
54). 
Other limitations include lack of comprehensive clinical data including lipid 
levels, lack of information regarding family history of CHD and smoking status 
(which are risk factors for CHD), in addition to weight, diet and exercise that may in 
turn affect lipid profiles and levels of patients. Availability of lipid levels and profiles 
would have confirmed some of the study conclusions. Misclassification of patients 
with regard to various diagnoses is also a possibility. In prevalent use, we cannot tell if 
the patients were switched from a previous medication due to side effects, even though 
assessing new users somewhat limits this problem. We also do not know how many 
internists versus sub-specialists are employed within the HMO. The data is relatively 
old, but it provides a unique opportunity to study the effect of drug benefit plan 
options and to compare changes in practice with the publication of recent guidelines in 
a 'real world' setting. 
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CONCLUSION 
Automated data from an HMO was used to describe LLA use in a large 
population of Medicare beneficiaries under managed care. Several important findings 
are noted. First, statins remain the most widely prescribed LLA. Second, a very low 
rate of combination drug use was found, which may, in part, explain why so many 
patients on LLAs do not reach their target cholesterol levels. This finding may help to 
increase the use of combination therapy, shown to be safe and effective, in the near 
future. Third, while the type of drug benefit plan option did not affect the choice 
among LLAs, comorbidities -mainly CHD and diabetes- seem to be among the main 
factors that influence drug selection, possibly through affecting the lipid levels, in 
accordance with A TPII guidelines that were the standard of practice at the time of this 
study. Patients with CHD were more frequently prescribed statin monotherapy and 
combination therapy and less frequently prescribed bile acid sequestrants. Diabetic 
patients used fibrates more frequently, and bile acid sequestrants and niacin less 
frequently compared to non-diabetics. 
Other observed differences include: females were more frequently prescribed 
bile acid sequestrants compared to males, a difference that disappeared when 
controlling for diabetes. Cardiologists prescribed bile acid more frequently and 
prescribed fibrates less frequently than internists; and finally, patients aged 65-69 were 
less likely to be prescribed a bile acid sequestrant compared to other age groups. 
These differences may have been in part related to the patient lipid profile as a 
result of comorbidities among other factors like body weight. Further research that 
includes lipid levels is required to investigate such findings. 
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T hie 1 Characteristics of prevalent users of lipid-lowering agents in an elderly 
p:pulation enrolled in a Medicare managed care health plan (n=lSSl) 
Characteristic N O/o 
Gender Females 946 (61.0%) 
Males 605 (39.0%) 
Age groups 65-69 686 (44.2%) 
Mean age =70.8 SD=4.4 70-74 555 (35.8%) 
75+ 310 (20.0%) 
Plan type No coverage 33 (2.10%) 
$1000 max 410 (26.4%) 
Full coverage 1108 (71.4%) 
Presciber specialty Cardiology 77 (5 .00%) 
Internal medicine 1234 (79.8%) 
Others 235 (15.2%) 
Missing 5 (0.30%) 
CHD diagnosis prior to prescription CHD diagnosis 811 (52.3%) 
No CHD diagnosis 740 (47.7%) 
Diabetes diagnosis prior to DM diagnosis 441 (28.4%) 
prescription No OM diagnosis 1110 (71.6%) 
Hypertension diagnosis prior to HTN diagnosis 1244 (80.2%) 
prescription No HTN diagnosis 307 (19.8%) 
.. 
SD==Standard Deviation, CHD=Coronary Heart Disease, HTN=Hypertension, DM=Diabetes 
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T ble 2 Characteristics of new users of lipid-lowering agents in an elderly 
p:pulation enrolled in a Medicare managed care health plan (n=345) 
Characteristic N % 
t-Gender Females 187 (54.2%) 
Males 158 (45.8%) 
Age groups 65-69 139 (40.3%) 
Mean age= 71. l SD=4.5 70-74 133 (38.5%) 
75+ 73 (21.2%) 
Plan type No coverage 22 (6.40%) 
$1000 max 110 (31.9%) 
Full coverage 213 (61.8%) 
Prescriber specialty Cardiology 31 (9.10%) 
Internal medicine 260 (76.3%) 
Others 50 (14.7%) 
Missing 4 (1.20%) 
CHO diagnosis prior to prescription CHD diagnosis 214 (62.0%) 
No CHD diagnosis 131 (38 .0%) 
Diabetes diagnosis prior to prescription DM diagnosis 116 (33 .6%) 
No DM diagnosis 229 (66.4%) 
Hypertension diagnosis prior HTN diagnosis 279 (80.9%) 
to prescription No HTN diagnosis 66 (19.1%) 
s D Standard Dev1at1on, CHD=Coronary Heart Disease, HTN=Hypertens1on, DM=Dtabetes 
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Table 3 Frequencies and percentages of different lipid-lowering agent drug 
groups for both prevalent and new users of lipid-lowering agents in an elderly 
population enrolled in a Medicare managed care health plan 
Drug group Prevalent users New users 
n O/o n O/o 
Statin 959 (61.8%) 226 (65.5%) 
Niacin 132 (8.50%) 39 (11.3%) 
Fibrate 205 (13.2%) 35 (10.1 %) 
Bile acid Sequestrant 230 (14.8%) 42 (12.2%) 
Combination 25 (1.60%) 3 (0.90%) 
Total 1551 (100%) 345 (100%) 
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T bl 4a Results of stratification of prevalent users of lipid-lowering agents in an el:er~y population enrolled in a Medicare managed care health plan with patient 
characteristics (n=lSSl) 
Sta tin Fib rate Bile Niacin Comb in Total 
N=959 N=205 N=230 N=132 N=25 N=1551 
J 61.8%}_ J13.2o/tl _114.8%1 _i8.5o/tl J1.6°/c1 11000/ci 
Gender *** 
p=0.0213 
Female 585 114 156 77 14 946 
% (61 .8%) (12.1%) (16.5%) (8.1%) (1.5%) (100%) 
Male 374 91 74 55 11 605 
% (61 .8%) (15.0%) (12.2%) (9.1 %) (1.8%) (100%) 
Age *** 
grou~ p=0.0006 
65-69 446 89 75 65 11 686 
% (65.0%) (13.0%) (10.9%) (9.5%) (1 .6%) (100%) 
70-74 328 76 99 40 12 555 
% (59.1%) (13.7%) (17.8%) (7.2%) (2 .2%) (100%) 
75+ 185 40 56 27 2 310 
% (59.7%) (12.9%) (18.1%) (8.7%) (0.7%) (100%) 
Drug benefit 
plan 
Full 704 134 159 91 20 1108 
% (63.5%) (12.1%) (14.4%) (8.2%) (1 .8%) (100%) 
$1000 max 235 67 68 35 5 410 
% (57.3%) (16.3%) (16.6%) (8.5%) (1.2%) (100%) 
No benefit 
% 20 4 3 6 0 33 
(60.6%) (12.1%) (9 .1%) (18.2%) (0.0%) (100%) 
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Table 4a continued 
Sta tin Fib rate Bile Niacin Comb in Total 
N=959 N=205 N=230 N=132 N=25 N=1551 
_161 .8°/tl_ _113.2%1 _i14.8°/tl_ _18.5%1 
_i1.6%1 _1100°/tl_ 
Prescriber *** Missing 
Special!I p=0.0092 n=S 
Cardiology 54 2 13 6 2 77 
% (70.1%) (2 .6%) (16.9%) (7.8%) (2.6%) (100%) 
Internal 
164 175 105 22 medicine 768 1234 
% (62.2%) (13.3%) (14.2%) (8.5%) (1 .8%) (100%) 
Others 136 38 40 20 1 235 
% (57.9%) (16.2%) (17.0%) (8.5%) (0.4%) (100%) 
CHO *** *** *** 
j>_<0.0001 j>_<0.0001 j>_=0.0467 
No CHO 419 107 140 67 7 740 
% (56.6%) (14.5%) (18.9%) (9.0%) (1 .0%) (100%) 
CHO 540 98 90 65 18 811 
% (66.6%) (12.1%) (11 .1%) (8 .0%) (2.2%) (100%) 
Diabetes *** *** *** 
No diabetes 
j>_=0.0032 j>_=0.0007 j>_=0.0336 
% 672 129 186 105 18 1110 
(60.5%) (11 .6%) (16.8%) (9.5%) (1 .6%) (100%) 
diabetes 287 76 44 27 7 441 
% (65.1%) (17.2%) (10.0%) (6.1%) (1 .6%) (100%) 
Hypertension 
No 
hypertension 184 43 51 24 5 307 
% (59.9%) (14.0%) (16.6%) (7.8%) (1 .6%) (100%) 
hypertension 775 162 179 108 20 1244 
% (62.3%) (13.0%) (14 .4%) (8.7%) (1 .6%) (100%) 
CH 
_ D Co~~nary Heart Disease, B1le=B1le acid sequestrant, Combm=Combmat10n therapy 
p- probabt ltty, ***=p<005, significant 
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Table 4b Results of stratific~tion of ~ew users of lipid-lowering agents .in an . 
elderly population enrolled m a Medicare managed care health plan with patient 
characteristics (n=345) 
Statins Fib rates Bile Niacin Combin Total 
N=226 N=35 N=42 N=39 (N=3) N=345 
J 65.5%}_ _110.1°/tl_ 112.2°/tl_ 111.3°/tl_ J0.9%1 J100°/tl_ 
Gender *** 
p=0.0168 
Female 117 15 30 23 2 187 
% (62.6%) (8.0%) (16.0%) (12 .0%) (1 .0%) (100%) 
Male 109 20 12 16 1 158 
% (69.0%) (12 .7%) (7 .6%) (10.1%) (0.6%) (100%) 
A_g_e _g_rou_E_ 
Age 65-69 92 14 13 20 0 139 
% (66.2%) (10.1%) (9.4%) (14.4%) (0.00%) (100%) 
Age 70-74 86 12 17 15 3 133 
% (64.7%) (9.0%) (12 .8%) (11 .3%) (2.3%) (100%) 
Age 75+ 48 9 12 4 0 73 
% (65.8%) (12.3%) (16.4%) (5.5%) (0.00%) (100%) 
Drug 
Cover~e 
Full 138 22 24 26 3 213 
% (64.8%) (10.3%) (11 .3%) (12.2%) (1.4%) (100%) 
$1000 max 73 11 15 11 0 110 
% (66.4%) (10.0%) (13.6%) (10.0%) (0.0%) (100%) 
No benefit 15 2 3 2 0 22 
% (68.2%) (9.0%) (13 .6%) (9.1 %) (0.00%) (100%) 
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T hie 4b continued a 
Statins Fib rates Bile Niacin Com bin Total 
N=226 N=35 N=42 N=39 (N=3) N=345 
J65.5°/ttl_ 110.1%}_ J12.2%1 J11.3%1 J0.9%1 J100%l 
*** Missing Prescriber 
s~cialty p=0.0008 (n=4) 
Cardiology 21 1 7 2 0 31 
% (67.7%) (3.2%) (22.6%) (6.5%) (0.0%) (0 .0%) 
Internal 
% 175 27 21 34 3 260 (67.3%) (10.4%) (8.1%) (13.1%) (1 .2%) (100%) 
Others 29 7 12 2 0 50 
% (58.0%) (14.0%) (24.0%) (4.0%) (0.0%) (100%) 
CHO *** 
_e.=00028 
No CHO 73 18 19 19 2 131 
% (55.7%) (13.7%) (14.5%) (14.5%) (1 .5%) (100%) 
CHO 153 17 23 20 1 214 
diagnosis (71.5%) (7.9%) (10.8%) (9.4%) (0.5%) (100%) 
% 
Diabetes *** 
_e.=0.0329 
No diabetes 143 21 34 29 2 229 
% (62.5%) (9.2%) (14.9%) (12.7%) (0.9%) (100%) 
Diabetes 83 14 8 10 1 116 
% (71.6%) (12.1%) (6.9%) (8.6%) (0.9%) (100%) 
Hypertension 
No 
Hypertension 44 7 9 5 1 66 
% (66.7%) (10.6%) (13.6%) (7.6%) (1 .5%) (100%) 
Hypertension 182 28 33 34 2 279 
% (65.2%) (10.0%) (11 .8%) (12.2%) (0.7%) (100%) 
CHD 
1>=- bCob~~nary Heart Disease, Bile=Bile acid sequestrant, Combin=Combinat1on therapy 
• -..,ro a ihty ***=p<005 . "ft 
, , s1gn1 tcant 
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T hie Sa Summary of p-values for statin users in an elderly population enrolled 
i: a Medicare managed care health plan stratified by patient characteristics 
(prevalent users n=9S9, new users n=226) 
Stratification variable Prevalent user _l!_-value New user _..l!_-value 
Gender 0.9933 0.2113 
Age group 0.0703 0.9644 
Plan type 0.0851 0.9259 
Prescriber specialty 0.1432 0.4348 
CHO diagnosis <0.0001 * 0.0028* 
OM diagnosis 0.0970 0.0928 
HTN diagnosis 0.4451 0.8256 
*p<O.OS=significant, CHD=Coronary Heart Disease, DM=Diabetes , HTN=Hypertension 
Table Sb Summary of p-values for fibrate users in an elderly population enrolled 
in a Medicare managed care health plan stratified by patient characteristics 
(prevalent users n=205, new users n=3S) 
Stratification variable Prevalent user _..l!_-value New user _..l!_-value 
Gender 0.0898 0.1552 
Age group 0.9176 0.7533 
Plan type 0.0934 0.9816 
Prescriber specialty 0.0092* 0.2968 
CHO diagnosis 0.1677 0.0835 
OM diagnosis 0.0032* 0.3995 
HTN diagnosis 0.6485 0.8903 
• p<0.05 significant, CHD=Coronary Heart Disease, DM=Diabetes, HTN=Hypertension 
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T hie Sc Summary of p-values for bile acid binding resins users in an elderly 
: ulation enrolled in a Medicare managed care health plan stratified by patient ~b!racteristics (prevalent users n=230, new users n=42) 
Stratification variable Prevalent user 1!_-value New user 1!_-value 
Gender 0.0213* 0.0168* 
Age group 0.0006* 0.3131 
Plan type 0.3565 0.8075 
Prescriber specialty 0.4584 0.0008* 
CHO diagnosis <0.0001 * 0.3004 
OM diagnosis 0.0007* 0.0329* 
HTN diagnosis 0.3263 0.6862 
• p<O.OS=significant, CHD=Coronary Heart Disease, DM=Diabetes , HTN=Hypertension 
Table 5d Summary of p-values for niacin users in an elderly population enrolled 
in a Medicare managed care health plan stratified by patient characteristics 
(prevalent users n=132, new users n=39) 
Stratification variable Prevalent user 1!_-value New user 1!_-value 
Gender 0.51 25 0.5254 
Age group 0.3594 0.1504 
Plan type 0.1293 0.7917 
Prescriber specialty 0.9760 0.1196 
CHO diagnosis 0.4638 0.1420 
OM diagnosis 0.0336* 0.2625 
HTN diagnosis 0.6270 0.2874 
• p<O.OS-s1gn1ficant, CHD=Coronary Heart Disease, DM=Diabetes , HTN=Hypertension 
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Table Se Summary of p-values for combination therapy users in an elderly 
opulation enrolled in a Medicare managed care health plan stratified by patient ~baracteristics (prevalent users n=25, new users n=3) 
Stratification variable Prevalent user ~-value New user ~-value 
Gender 0.6059 NA** 
Age group 0.2361 NA** 
Plan type 0.5490 NA** 
Prescriber specialty NA** NA** 
CHO diagnosis 0.0467* NA** 
OM diagnosis 0.9614 NA** 
HTN diagnosis NA** NA** 
*p<O.OS=significant, CHD=Coronary Heart Disease, DM=Diabetes, HTN=Hypertension 
**NA=Chi-Square test not accurate because 25% of cells or more have expected counts less 
than five. 
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Persistence of lipid-lowering therapy: Influence of drug benefit plan options on 
time to discontinuation. 
ABSTRACT 
Background Many health maintenance organizations (HMOs) have implemented 
programs providing varying degrees of annual drug coverage for Medicare 
beneficiaries enrolled in their plans. The unintended effects of such policies are 
important to consider. Several studies have documented the beneficial effects of lipid-
lowering agents (LLA), but long-term persistence to therapy is crucial to achieve this 
benefit. 
Objective To determine the effect of drug plan benefit options among elderly 
patients enrolled in managed care on persistence to LLAs controlling for potential 
confounders. 
Methods A retrospective cohort study using 322 older adult members in an HMO 
operating in Massachusetts who were prescribed an LLA between July 1, 1994 and 
June 30, 1996 among individuals with no dispensing during the previous one year 
prior to July 1, 1994, and with initial dispensing prior to January 1, 1996. 
Survival analysis was used to examine differences in discontinuation of LLAs 
between different drug benefit plans controlling for potential confounding effects of 
patient sex, age (2'.:70), hospitalization for CHD prior to initial prescription, 
53 
hypertension or diabetes mellitus diagnoses prior to initial prescription, statin (a class 
of lipid-lowering agents) use, and number of other medications used (~J). The 
outcome measure used was time until discontinuation, defined as greater than 180 
days between refills or between the last refill and the end of the study period. 
Results The overall discontinuation rate increased with time from 18.3% at 6 
months, to 46.4% at 12 months, to 66.3% at 18 months. 
In the bivariate models, males had lower discontinuation than females 
(p=0.0078), CHD patients had lower discontinuation than non-CHD patients 
(p=0.0424), and statin users had lower discontinuation than non-statin users 
(p=0.0004). In the multivariate model, a significant difference existed with statin use 
(HR=0.536; CI=0.375-0.766; p=0.0006), indicating that statin users were less likely to 
discontinue compared to nonusers. No significant differences existed with plan type, 
gender, age, CHD, diabetes, and number of other medications. 
Conclusion Persistence to lipid-lowering therapy among elderly patients declines 
over time with the greatest drop during the first year. We did not find an association 
between drug benefit plan options and discontinuation. Our findings suggest that 
adequate payment mechanisms are not enough to guarantee persistence. To achieve 
the desired benefit of therapy, long-term commitment to patient education, monitoring 
and reinforcement with a multidisciplinary approach (including pharmacists, nurses, 
physicians and dieticians) is warranted. 
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BACKGROUND 
During the 1990s, increasing numbers of Medicare beneficiaries were 
becoming enrolled in managed care plans. Between 1989 and 1994, the HMO share of 
Medicare almost doubled [1]. In 1997, managed care enrolled 14.9% of the Medicare 
population (5 .6 million) [2] , and in year 2000, about 16% of Medicare beneficiaries 
were enrolled in Medicare plans associated with HMOs [3]. These differ from 
traditional Medicare plans in that the enrollees receive their coverage from the HMO 
rather than individual providers in private practice [3]. 
The growth in medical care expenditure is an important issue. The cost of 
pharmaceuticals has been reported to be among the fastest rising components of 
healthcare costs, with a 17.3% increase in national expenditures for prescription drugs 
from 1999 to 2000 [4]. Spending on prescription drugs has increased at double-digit 
rates for the past decade and is now the third largest component of healthcare 
expenditures behind hospital care and physician services [5]. Policy responses have 
included limits on prescription costs, restriction on the supply of healthcare, and 
shifting of the financial risk to providers and beneficiaries [6-8]. Patient cost-sharing 
through deductibles, coinsurance, and co-payments is one technique increasingly 
being used to contain medical costs in general, and prescription costs in particular, to 
deter patients from unnecessary use [6-9]. There is, however, a concern that necessary 
utilization could be reduced, which may in tum increase the risk of adverse health 
consequences and resulting costs [4, 6-8, 10-12]. Cost-sharing does not affect 
everyone equally; those with lower incomes, like many elderly, are more likely to 
reduce medication use than those with higher incomes. Stuart et al. [ 13] found that the 
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probability of the elderly medicating a health problem decreases 2-3% for every $3000 
reduction in income for annual incomes below $18,000. Low income populations 
appear to be sensitive to drug co-payments as low as 10-15% of average prescription 
expenses with declines of 5-10% observed in drug utilization [14]. 
When the Medicaid program in New Hampshire placed a limit of 3 
reimbursable medications that a patient could receive per month, there was a 30% 
drop in the number of prescriptions filled per month among 10, 734 enrollees, and 
reduced use of essential medications like insulin and antihypertensi ves [ 15]. Several 
other studies have reported a decrease in prescription filling due to cost-sharing [16-
18]. At the same time, changes in cost-sharing for one service should not be 
considered separately from another service, since patients may simply shift the type of 
service sought to deal with the health problem [6]. The 3-drug limit placed by 
Medicaid in New Hampshire increased the risk of nursing home admissions and 
overall healthcare costs [19]. The Medicare population is demographically different 
from the Medicaid population, and thus its response to such policies may differ. 
Research has shown, however, that Medicare patients who lack coverage receive 
fewer prescription medications than those with coverage [11 , 20] and that medication 
restriction is common in older adults who lack prescription drug coverage [12] . Other 
studies have shown the negative effect of reducing drug coverage among the poor 
elderly and the consequences of inadequate coverage for older adults patients 
receiving medications that can prevent serious adverse health consequences [ 4, 21] . 
Comparing Medicare beneficiaries with and without drug coverage shows those with 
poor health and no coverage fill 36% fewer prescription than those with coverage, and 
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that those with incomes below poverty line and without coverage fill 48% fewer 
annual prescriptions [I I] . 
Starting January I , 1994, an HMO in central Massachusetts introduced a policy 
in which older adult plan members were able to choose among 3 drug benefit plans. 
This research explored the effects of this policy on discontinuation rates of lipid-
Iowering agents (LLA), group of drugs of well-documented benefit for both primary 
[22-25] and secondary [26-30] prevention of coronary heart disease (CHD). 
CHD continues to be the leading cause of death among the United States (US) 
population [31-33], and worldwide [32, 34], despite reported declines in mortality 
during this century [35]. Cardiovascular disease accounts for 950,000 deaths annually 
in the US, including 460,000 from CHD [31 ], and 85% of those who die from CHO 
are 65 years of age or older [31] . In 1990, there were 489, 171 deaths attributed to 
CHD [35], and 675,000 patients were discharged from US hospitals with a primary 
diagnosis of myocardial infarction [36], and hospitalization for CHD continues to 
increase [37]. The prevalence of nonfatal CHD among US adults aged 40 and above 
was reported to be 11.8% [33]. It remains an important disease with significant 
burden. Estimated yearly costs of CHD for medical treatment and lost wages in the US 
range from $50 billion to $100 billion [31 , 38, 39]. 
High cholesterol, specifically elevated low-density lipoprotein cholesterol 
(LDL-C), is a major cause of CHD [38, 40-42], a link that was first made by the 
Framingham Heart Study [43]. 
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Currently, the American Heart Association estimates that 70 million adults in 
the US have total cholesterol levels>200mg/dl, and that at least 40% of these 
individuals have cholesterol levels in excess of240mg/dl [31 ,44]. 
Hypercholersterolemia remains under-treated [ 44-46] especially in the elderly 
[47-49]. Elderly patients fail to receive indicated lipid-lowering medications as often 
as 80% of the time [47, 49] and even fewer achieve their target cholesterol [48, 49]. 
This may be because physicians fail to prescribe LLAs, patients fail to consume them, 
or both [49]. The use of statins in clinical practice were shown to lead to reductions in 
LDL-C that were significantly less than those projected in the pharmaceutical 
manufacturer guidelines, a gap that could reflect poor adherence in clinical practice 
settings [50]. 
Adherence to cholesterol lowering therapy is expected to be a problem based 
on previous reports showing that compliance with drug therapy for chronic diseases is 
frequently sub-optimal [51]. The cumulative treatment discontinuations among long 
tenn regimens of all types is about 50% of patients at the first year [51-58] , and there 
are no reasons for discontinuation rates in LLA to be any different [51 ], especially 
when considering that hypercholesterolemia is a chronic condition that is perceived by 
the patient as having deleterious health consequences that are far in the future [59]. 
Compliance/adherence is defined as the extent to which a patient's behavior 
corresponds to the physician' s therapy recommendations [60, 61]. Filling the 
prescription is the first step of the compliance process [51 , 62]. Refill persistence is a 
form of compliance while failure to obtain refills or stopping the medication sooner 
than the physician's recommendation are forms of noncompliance [61 , 63] . Drug 
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discontinuation rates are useful tools for evaluating patients' failure to adhere to 
therapy [39, 61, 64] and are commonly used as a measure of compliance rates [51 , 54, 
61 ]. They are useful mainly for medications intended for long-term use and 
population-based studies that assess drug use retrospectively [ 61]. 
Noncompliance with medication has a significant negative health impact [65-
73], and is estimated to cost the US $25 billion annually when indirect costs are 
included [74]. In a number of chronic illnesses, it has been associated with increased 
hospitalization [66, 75, 76] and poor outcomes in the long run [68-73] . The stark 
contrast in benefit experienced between compliant and noncompliant patients was 
demonstrated in the West of Scotland Coronary Prevention Study (WOSCPS) [22]. By 
the end of the 5 year follow-up, the relative risk reduction for cardiovascular death in 
compliant patients (who took more than 75% of prescribed drug) was 37% compared 
to 32% in the less compliant group [77] , and the need for revascularization procedures 
was reduced by 46% in the compliant group compared to 37% in the less compliant 
patients [78]. In the Lipid Research Clinics Coronary Primary Prevention Trial [79], a 
randomized placebo controlled study of 3806 patients followed for 7 years, only half 
of the patients took the recommended dose of six packets of cholestyramine (24gm) a 
day. The study documented an overall 19% lowering of cardiovascular risk. However, 
among patients taking the full-recommended dose, the reduction was twice as great 
(39.3%), and there was a dose response relationship [24, 52, 79, 80]. A significant 
reduction in recurrent myocardial infarction among 5595 patients in the UK was 
observed in patients taking statins with adherence of 80% or more compared to those 
not tak' · 
mg statms (RR 0.19; CI=0.08-0.47). For those with adherence of less than 80%, 
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there was no significant reduction in recurrent MI risk [81]. Such differences were not 
observed in a community setting when Andrade et al. [82] compared rates of 
hospitalizations and LDL-C levels after discontinuation of antihyperlipidemic therapy. 
A possible explanation for this finding is that most patients discontinued therapy 
before an effect could be observed, or failed to achieve desired LDL-C reduction. 
The public health importance of adherence for gaining a widespread benefit 
from LLAs is emphasized by the dominance of atherosclerotic disease as the major 
cause of morbidity and mortality in the United States [33, 35, 36], and the efficacy of 
cholesterol drugs in obtaining benefits in both primary [22-25] and secondary [26-30] 
prevention ofCHD. The success of an intervention requires that patients' adherence to 
treatment instructions is maintained throughout. The economical and widespread 
achievement of benefits depends on all risk-qualified patients obtaining a high level of 
adherence to these regimens of proven efficacy. Adherence is the critical link between 
prescription and treatment success [ 41 , 51 , 83]. 
Little is known about persistence to lipid-lowering therapy among older 
patients since studies have preferentially enrolled younger patients or informed 
subjects they were being monitored, thus reducing generalizability of the results [49, 
84, 85]. Elderly patients are of particular concern since they may exhibit an increased 
susceptibility to adverse events [86] because of deficits in physical dexterity, cognitive 
skills, and memory, as well as the large number of medications they are prescribed 
[8?]. Elderly patients are also more likely to discontinue medications than younger 
patients [49, 64, 88] . 
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Targeting persistence-enhancing interventions so that they have the most 
leverage and potential benefit requires knowledge of time during therapy where 
discontinuation is most likely, and which patient subgroups are of high risk. 
Furthennore, discontinuation rates are important to estimate population level cost and 
benefit of LLAs in actual practice, especially since discontinuation rates in HMO 
clinical practices were reported to be higher than those in clinical trials [56]. Our 
objectives were to describe trends of LLA use in actual practice, identify patient 
characteristics that predict poor persistence, and explore the effect of drug benefit plan 
option on persistence to these drugs. We hypothesized that members of the full drug 
benefit plan would have better persistence with LLAs compared to the $1000 
maximum or no drug coverage plans. 
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METHODS 
Data source and study population 
The study is a retrospective cohort design among older adult enrollees 
(Medicare beneficiaries) of an HMO operating in Massachusetts, who were 
continuously enrolled in the plan during the period of July I , 1993 - June 30, 1996, 
and were prescribed a LLA. These members were able to choose among 3 drug benefit 
options starting January 1, 1994: full coverage for prescription drugs, a maximum of 
$1000/year in coverage, or no drug coverage. Those selecting full coverage paid an 
additional premium of $72.50/month ($870/year). Those with a $1000 maximum 
coverage paid an additional $39.16/month ($469.92/year). Those without coverage 
paid no additional premium. 
Information on demographic characteristics, drug benefit plan type, 
prescriptions, ambulatory visits, hospitalization, and diagnoses was available for this 
population cohort. The population cohort was comprised of2229 members. We 
deleted 325 members who switched from the original plan chosen on January 1, 1994 
since we were unable to explore the effects of the type of drug benefit as a main 
predictor of adherence in these individuals. Of those, 251 (77 .2%) switched from the 
full coverage plan, 61 (1 8.8%) from plan the $1000 maximum plan, and 13 (4.0%) 
from the no coverage plan. The final plans chosen by these patients in this study 
period were the full coverage plan in 89 patients (27.4% ), the $1000 maximum in 186 
(57.2%), and the no coverage plan in 50 (15.4%). 
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We then identified patients with a prescription of an LLA between July 1, 
1994 and June 30, 1996 among individuals with no prior dispensing during the 
previous one-year prior to July 1, 1994, in order to identify relatively new users of 
LLAs, and with initial dispensing prior to January 1, 1996. The definition of new users 
has been previously described [64, 89]. 
This study examined differences in discontinuation of LLAs between different 
drug benefit plans controlling for potential confounding effects of patient sex, age, co-
morbidities (CHD, hypertension or diabetes mellitus)-which are among the CHO risk 
factors in the National Cholesterol Education Program (NCEP) guidelines [38, 41 ]-
number of medications used, and statin (a class of LLAs) use. 
Members with greater than a 6-month period (180 days) between refills or 
between the last refill and the end of the study period were considered to have 
discontinued the drug. Changing the type of LLA was not considered as 
discontinuation. Patients who had more than one prescription refilled prior to a 6-
month period with no refills were not considered to have discontinued. 
In previous research, Andrade et al. [56] used a 6-month period or more (180 
days) between refills to flag potential discontinuation. Jackevicius et al. [64] used 
having a prescription every 120 days to define adherence and used 180 days for a 
sensitivity analysis. 
For these patients we determined the gender; age; drug benefit plan type; 
presence of comorbodities including CHD, diabetes, and hypertension; and number of 
otherm d. · 
e 1cations used by the patient. Drug benefit plan type was categorized as full 
coverage versus partial or no coverage. Age was categorized into two groups: below 
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10, and 70 years or older. This was based on the frequency distribution of age groups 
in this population cohort. A patient was considered to have CHO if there was a 
hospitalization for CHO or a diagnosis for CHO (ICD-9 code= 410-414) prior to the 
LLA prescription or during the one-year prior to the study period. Patients with a 
diabetes diagnosis (ICD-9 code=250) prior to the LLA prescription or during the one-
year prior to the study date were labeled diabetic, and patients with a hypertension 
diagnosis (ICD-9 code= 401 -405) prior to the LLA prescription or during the one-year 
prior to the study date were regarded as having hypertension. Number of other 
medications used at the time of the first dispensing was determined by evaluating a 
45-day period prior to the initial dispensing, and transformed into two groups: 0-2 
other medications, or 3 and more. 
Statistical analyses 
Descriptive statistics were used to determine various patient characteristics. 
Survival analysis was used to assess the effect of drug benefit options on the 
discontinuations of LLAs. The outcome variable considered was time until 
discontinuation. The main predictor variable was type of drug benefit plan option. 
Other covariate predictors included in the model include age, gender, CHD, diabetes, 
hypertension, and number of other medications used. 
Kaplan-Meier (KM) curves of the main predictor variable and the covariate 
predictor variables were independently constructed, and the log-rank statistic was used 
to evaluate group differences for each variable independently. 
Assessment of the proportional hazards (PH) assumption for each of the 
predictor variables was carried out using the graphical approach of the log-log survival 
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curve described by Kleinbaum [90]. This approach involves comparing the log-log 
plots of KM survival curves for different categories of each variable separately. The 
PH assumption is satisfied unless there is a strong evidence of nonparallel ism [90] . 
Stratification was used when the assumption was violated as described by 
Kleinbaum [91]. Testing the no-interaction assumption was also carried out in order to 
determine the type of model to be used (interaction model or no-interaction model). 
This was accomplished by calculating the difference between the - 2L statistics of the 
full and reduced models. The full model has all the variables plus interaction terms 
between the stratification variable and the other variables in the model, while the 
reduced model has only the variables and no interaction terms. Testing for significance 
was carried out using the chi-square distribution with degrees of freedom equal to the 
number of interaction terms (difference in terms between the 2 models). A difference 
in the - 2L value that was less than the chi-square statistic indicated no significant 
interaction [91]. 
Co-linearity between various variables in the model was tested using testing by 
SAS proc corr. as suggested by Delwiche and Slaughter [92] to give correlation 
coefficients described by Johnson and Bhattacharyya [93]. 
Interaction assessment was performed by the chunk test described by 
Kleinbaum [94] , which involves calculating the difference between - 2L statistics of 
the full and reduced models. The full model has interaction terms while the reduced 
does not. Chi-square distribution was used to test for statistical significance of this 
difference with degrees of freedom equal to the number of interaction terms 
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(difference in terms between the models). A difference that was less than the chi-
square statistic indicated no statistically significant interaction. 
Finally a Cox proportional hazards model that incorporated the main predictor 
variable and other independent variables (as potential confounders) was constructed. 
Confounding assessment was also carried out by removing each independent variable 
and assessing the effect on the parameter estimate of the main predictor variable. 
Statistical significance was set at p<0.05, and the estimates were reflected by a 95% 
confidence interval. All statistical analysis was carried out using SAS statistical 
package version 8.01. 
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RESULTS 
Descriptive statistics 
A total of 322 patients met our inclusion criteria and were selected for the 
study. The mean age of these patients was approximately 70 years of age. There were 
more female patients (n= l 87; 58.1%) than males (n=135; 41.9%) in our study 
population. 
Most of these patients were covered by the full coverage drug benefit plan 
(n=202; 62.7%), nearly a third of them by the partial coverage plan (n= l08; 33.5%), 
and a small percentage by the no coverage drug benefit plan (n=12; 3.7%). 
As for the type of LLA in the initial prescription, statins were the most widely 
used (n=188; 58.4%), followed by bile acid sequestrants (n=75 ; 23.3%) then niacin 
(n=34; 10.56%). Fibrates were the least used in this patient population (n=25; 7.8%). 
Approximately half of this patient population was hospitalized for CHO prior to the 
initial LLA prescription (n= l 59; 49.4%), 22.1 % had a diabetes diagnosis prior to the 
initial prescription (n=71 ), and most had a hypertension diagnosis prior to the initial 
prescription (n=231 ; 71.7%). The mean number of other medications used by these 
patients based on NOC-codes was 2.4 medications. This information is presented in 
Table 1. 
The coding of various variables in subsequent bivariate and multivariate 
analyses is summarized in Table 2. Because of the low percentage of patients in the no 
coverage plan benefi t, drug benefit plan type was further categorized as full coverage 
(n==202; 62.7%) versus partial or no coverage (n=120; 37.3%). Age was converted into 
a dichotomous variable with age below 70 years in one group, accounting for 50% of 
67 
the patient population (n=161), and 70 years or older in the other group. Number of 
other medications was also converted into a dichotomous variable with 3 or more 
medications in one group (n=125; 38.8%) and 0-2 medications in the other group 
(n=l97; 61 .2%), and type ofLLA at the initial dispensing was further categorized as 
statin user (n=188; 58.4%) versus non-statin user (n= l34; 41 .6%). 
KM survival curves for the various variables are shown in Figures 1 a--8a in 
Appendix D. Table 3 summarizes the results of the log rank test for these curves and 
the discontinuation rates at 6 months, 12 months, and 18 months overall and stratified 
by the variables. 322 patients were followed for 6 months, 235 for 12 months, and 187 
for 18 months. 
By the end of the study period, a total of 126 (39 .1 % ) patients had 
discontinued their medication. Twenty-six of these had more than 6-months between 
refills, and the remainder (n= 100) had a more than 6-months between last refill and 
end of the study. The discontinuation increased with time, with 59 (18.3%) 
discontinuing at 6 months, 109 (46.4%) at 12 months, and 124 (66.3%) at 18 months. 
A significant difference existed between genders, with males having lower 
discontinuation than females (Graph 2a). The discontinuation increased from 11.9% 
at 6 months, to 39.8% at 12 months, to 54.9% at 18 months in males, and from 23.0% 
at 6 months, to 50.3% at 12 months, to 73 .2% at 18 months in females (p=0.0078). 
A significant difference also existed between those who were hospitalized for 
CHO and those that were not, with CHO patients having lower discontinuation than 
non-CHO patients (Figure 4a). The discontinuation increased from 15. 7% at 6 
months, to 40.9% at 12 months, to 59.1% at 18 months in CHD-patients, and from 
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20_9% at 6 months, to 51.2% at 12 months, to 72. 7% at 18 months in non-CHO 
patients (p=0.0424). 
Finally, a significant difference existed between statin users and non-statins 
users, with statin users having better persistence than non-statin users (Figure 8a). The 
discontinuation increased from 23.9% at 6 months, to 55.0% at 12 months, to 77.3% at 
18 months in non-statin users, and from 14.4% at 6 months, to 38.7% at one year, to 
56.6 % at 18 months in statin users (p=0.0004). 
The survival curves were slightly higher for members of the full coverage plan 
compared to members of the no or $1000 maximum plans (Figure la), members below 
70 years of age compared to age 70 or above (Figure 3a), diabetics compared to non-
diabetics (Figure Sa), non-hypertensives compared to hypertensives (Figure 6a), and 
those with number of other medications 0-2 compared to 3 or above (Figure 7a), but 
these differences did not reach statistical significance. 
Figureslb--8b in Appendix Dare the log-log plots of KM survival curves for 
assessment of the proportional hazards (PH) assumption for each of the predictor 
variables. The PH assumption was satisfied in all variables except hypertension 
(Figure 6b ), since there is a strong evidence of nonparallel ism by the crossing of the 
two lines. 
Table 4 shows the results of the testing no interaction assumption. No 
significant interaction terms existed between hypertension and the other variables that 
were to be included in the model. 
The highest correlation coefficient between variables was 0.26127, indicating 
no co-linearity between variables. 
69 
Table 5 summarizes results of interaction assessment for the variables that 
were to be included in the model with the main predictor variable of plan type. No 
significant 3-way or 2-way interactions existed. 
In the multivariate model, a significant difference in discontinuation existed 
with statin use (HR=0.536; CI=0.375-0.766; p=0.0006), indicating that statin users 
were less likely to discontinue compared to nonusers. No significant differences 
existed with plan type, gender, age, CHD, diabetes, and number of medications. These 
results are summarized in Table 6. 
Table 7 shows the results of confounding assessment. None of the variables 
when removed caused large changes in the parameter estimate (B) for the main 
predictor variable plan type. 
The changes in the odds ratio when only statin use is kept in the model with 
the main predictor are presented in Table 8. It shows only minor changes in the hazard 
ratio of the main predictor variable, plan type, when these 2 variables are kept in the 
model (HR=0.851; CI=0.594-1.221 ; p=0.3820) compared to the full model 
(HR=0.877; CI=0.610-1.260; p=0.4777) with the rest of the variables included. 
Multivariate adjusted survival curves for our main predictor (drug benefit plan 
type) stratified by hypertension and adjusted for gender, age, CHO diagnosis, diabetes 
diagnosis, number of medications, and statin use are presented in Figure 1. 
Multivariate adjusted survival curves among hypertensives is presented in Figure 2, 
and among non-hypertensives in Figure 3. 
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DISCUSSION 
Administrative databases with prescription refill records are increasingly being 
used in pharmacoepidemiologic research. They provide a cost-effective alternative to 
post-marketing clinical trials in a real world setting [95, 96]. Automated databases can 
be used to assess prescribing patterns and trends of drug use [97-99] as well as impact 
of policies [100]. They have often been successfully used in adherence research [55, 
61 , 64, 89, 101 ]. Pharmacy refill data is considered a more objective measure than 
self-reports, which can overestimate compliance [101 , 102]. Although filling the 
prescription is not identical to consuming the drug, patterns of prescription filling 
represent the most accurate way of estimating actual medication use in large 
populations [55]. The effectiveness of using automated databases for studying 
discontinuation rates in primary care settings has been well demonstrated [62, 103]. 
In this research, we used data from an HMO to study persistence of LLAs in a 
group of elderly patients, mainly to study the effect a drug benefit plan option has on 
the persistence of these drugs, controlling for potential confounders including gender, 
age, comorbidities (CHD, diabetes, and hypertension), number of medications, and 
statin use. 
The study population had a high prevalence of CHD (49.4%), diabetes 
(22.1 % ), and hypertension (71 . 7%) compared to reported prevalences in the general 
population [33 , 104, 105], which is understandable considering it is a population of 
older adults being treated for hypercholesterolemia. More than half of the patients also 
chose the full coverage benefit plan (62.7%), a fact which can be explained by the 
higher drug use in this age group compared to younger patients [86, 106]. Statins were 
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the most widely used LLA (58.4%) consistent with other reports [83 , 107-110]. They 
are the most effective for LDL-C reduction and the best tolerated among LLAs [50, 
S3, 111] and are of well-documented benefit for both primary [22, 23] and secondary 
[26-28] prevention of coronary heart disease (CHO). 
The one-year LLA discontinuation rate of 46.4 % was higher than those 
reported in clinical trials (ranging from 4-15%) [ 56] and that reported by Andrade et 
al. (32%) [56]. Higher discontinuation rates have also been reported. In an Australian 
practice setting, a 60% discontinuation rate over one year was reported, with 56-57% 
for statins, and 78% for gemfibrozil [112]. The one-year discontinuation rate for 
statins was found to be 38.7%, higher than that reported by Andrade et al. [56]- which 
was 15% for lovastatin- and lower than that reported by Simons et al. [112] (56-57%). 
O'Connor et al. [113] also reported a 52% discontinuation rate for lovastatin, and 
Benner et al. [ 49] a 61 % rate. The 6-month discontinuation rate that we found for 
statins (14.4%) was lower than that reported by Jackevicius et al. [64] (25%). 
In general, all findings suggest that the discontinuation rates for LLAs are high 
[49, 56, 64, 112, 113], and more than those reported in clinical trials [56]. To obtain 
the reported full benefit of these drugs [22-30], it is important to ascertain factors 
contributing to discontinuation in order to target subpopulations that are more likely to 
discontinue. 
We found that that discontinuation increased progressively with the increasing 
duration of treatment, consistent with what other studies previously reported [ 49, 51 , 
64]. Overall LLA discontinuation increased from 18.3% at 6 months, to 46.4% at 12 
months, and to 66.3% at 18 months, and statin discontinuation rates increased from 
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14.4% at 6 months, to 38.7% at 12 months, to 56.6% at 18 months. We noticed that 
the increase in discontinuation became relatively slower after the first year. 
Other factors explored in this research include drug benefit plan option as a 
main predictor, gender, age (~70), number of medications (~3), previous 
hospitalization for CHD, diabetes diagnosis, and hypertension diagnosis. 
Our main predictor, drug benefit plan option, was not found to be significantly 
associated with non-persistence (HR=0.877; CI= 0.610-1.260; p=0.4777). The KM 
survival curves for the fu ll coverage were higher than the no or partial coverage and 
the adjusted survival curves for full plan among hypertensives was also higher than the 
curve for no or partial coverage, indicating a trend of better persistence with the full 
coverage members- but this difference did not reach statistical significance. Financial 
effects have previously been explored in several studies. Financial incentives have 
been shown to improve compliance in patients [114]. Eighty-five percent of 132 
physicians surveyed in eastern Massachusetts reported that inability to afford 
medication was a problem for some of their patients [115]. Thirty-eight percent of 
patients that discontinued their medication in a follow up study one year after the 
conclusion of the 4S study blamed acquisition costs [116]. Cost of medications was 
also found to be among factors contributing to noncompliance in the elderly [66, 117]. 
Medicare patients who do not have prescription drug coverage are reported to face 
higher out of pocket expenditures and are more likely to let prescriptions go unfilled 
or skip doses to save money [118] . Elderly Medicare beneficiaries with CHO who lack 
drug coverage were shown to have significantly lower rates of statin drug use ( 4. I%) 
compared to those with drug coverage (27.4%) (p<0.001) [119]. 
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Furthermore, Medicare beneficiaries with capped dollar amounts on 
prescriptions have been reported to take steps to decrease their out of pocket 
prescription costs, including taking samples from physicians, taking less than the 
prescribed dose, and discontinuing the prescribed medication [120]. In a cross 
sectional study of 4896 older adults aged seventy or older who regularly took 
prescribed medications, based on a national survey, medication restriction was 
reported in 8% of subjects with no coverage, 3% of those with partial coverage and, 
2% with full coverage (p<0.01 for trend) [12]. Still, research on elderly patients taking 
LLAs specifically has shown high discontinuation rates in patients with drug coverage 
[49, 55, 64, 101]. Benner et al. [49] found a 43% persistence of statin therapy in 6 
months and only 1 in 4 were adherent in five years. Persistence was defined as 
proportion of days covered by a statin of 80% or more. Cost was not an issue here 
since patients received their medication for free or a $5 co-payment (patients were 
from the New Jersey Medicaid and Pharmaceutical Assistance to the Aged and 
Disabled program who were 65 or older). Jackevicius et al. [64] found a two-year 
adherence rate (defined as having a statin prescription refill every 120 days) of 36. l % 
in patients with coronary artery disease and 25.4% in patients of primary prevention 
(without CHD) in a Canadian population in which costs are covered except for a small 
co-payment. Avom et al. [55] found that patients failed to fill their LLA prescriptions 
about 40% of the time over one year in Medicaid (New Jersey Medicaid and 
Pharmaceutical Assistance to the Aged and Disabled program) and Quebec (Quebec ' s 
provincial medical care program)- systems with comprehensive drug benefits for their 
patients. In addition, a study in British Columbia, where there are various levels of 
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coverage provided by the provincial government and patients can buy additional 
private insurance to cover their medication costs, found no significant difference 
between adherent and non-adherent patients with respect to type of provincial 
coverage in a X2 analysis (p=0.27), and no difference in the proportion of patients with 
additional coverage (56% versus 53%; p=0.76) [121]. One study assessing the effects 
of a 3-tier pharmacy benefit in chronic diseases found discontinuation to be higher for 
patients who switched from a 2-tier plan to a 3-tier plan compared to those who stayed 
in the 2-tier or 3-tier plans, but this study did not look into switching to a generic or 
brand formulary alternative [122] . Our findings (no association of drug benefit plan 
options and discontinuation) suggest that adequate payment mechanisms are not 
enough to guarantee persistence, since we could not document a statistically 
significant difference in discontinuation between members who are fully covered for 
their medication, and members who are not and may, in turn, have problems with their 
medication costs. 
Gender was noted to be significantly associated with discontinuation in 
bivariate analysis (p=0.0078), but was no longer associated when adjusting for other 
variables in the model. Results in previous studies have been inconsistent with regard 
to gender effects on compliance [117] , with some reporting associations [64, 89] and 
others not [76, 123]. Our results indicate no association, even though a trend of better 
persistence with males was documented. 
Statin use was significantly associated with better adherence in bivariate 
(P==0.0004) and multivariate analyses (HR=0.536; CI=0.375-0.766; p=0.0006). 
Adherence to lipid-lowering therapy has been previously associated with receiving a 
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statin [55, 64, 1I2], since they are generally more tolerable than other LLAs [83 , 101 , 
109, 111] and side effects have been commonly cited as reasons for noncompliance 
[56, 124]. 
Previous hospitalization for CHD was significantly associated with better 
adherence in the bivariate analysis (p=0.0424), but was no longer associated in the 
multivariate analysis after controlling for the other variables. Although studies have 
indicated better adherence to lipid-lowering drugs in secondary prevention compared 
to primary prevention [51 , 55, 64, 67] , a number of these studies did not have an 
element of financial issues since patients were covered for the price of the drug except 
fora small co-payment in some cases [49, 55, 64, 101]. Furthermore, research has 
shown that targeting patients during a hospitalization for an acute event or intervention 
procedure can improve persistence [42, 88, 125, 126], which is why current NCEP 
ATPIII guidelines recommend initiating lipid-lowering drug therapy at hospital 
discharge, not after [41, 88]. In our study, we looked for a previous hospitalization 
prior to the prescription date, but we could not tell if the prescription was given while 
the patients were in the hospital or some time after discharge. This timing of treatment 
initiation may in turn affect patient persistence. 
Presence of other comorbidities, diabetes and hypertension, have been 
previously associated with discontinuation, causing better persistence [49, 55, 64]. 
Lower compliance with comorbidities has also been reported, possibly related to a 
more complex regimen with comordities [89] . The asymptomatic nature of 
hyperr ·d · 1P1 em1a may also contribute to the lower adherence to LLAs when a 
symptomatic comorbidity like diabetes exists [89]. We did not find such associations 
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in the univariate analysis for both these comorbidities, and could not find an 
association with diabetes in the multivariate analyses. The recent A TPIII guidelines, 
that were not available at the time of the study, are more aggressive in treatment of 
hypercholerterolemia among diabetics compared the A TPII guidelines that were 
available at the time of our study. The ATPIII guidelines place patients with diabetes 
in the highest risk group of CHD-risk e·quivalent with a target LDL-C of 100 mg/di. In 
the prior A TPil guidelines, a patient had to have another risk factor along with 
diabetes to have a target LDL-C of 130 mg/di. This could in turn cause better 
awareness of the cardiovascular risk among diabetics since the time of the study. Thus, 
we might observe better adherence of diabetic patients with this growing awareness 
using more recent data that coincides with the newer guidelines. 
Previous studies have been inconsistent with regard to the effect of number of 
medications [49, 55, 61, 64, 124] and age [49, 64, 89, 121 , 127] on persistence. Some 
have even reported lower adherence with lower number of medications [ 121 ], possibly 
because subjects with more medications are sicker and could be more attentive to 
taking their drug therapy [121]. We did not find a significant association between 
number of other medications 2:3 or age 2:70 on persistence to LLA. 
Improving patient understanding of cardiovascular risk, medication regimens, 
and benefits of persistence is expected to enhance adherence to LLAs [ 51, 80, 109], as 
patient education has shown to improve compliance in other diseases like hypertension 
[ 1 O l, 128-130] -To achieve the desired benefit of therapy and improved population 
health long term .t . d . . . d . -~ 
' - comm1 ment to patient e ucat10n, momtonng an re11uorcement 
with a multidisciplinary approach, including pharmacists, nurses, physicians, and 
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d. · ·ans 1·s warranted [39, 42, 49, 51, 63, 101, 109]. This approach can emphasize the tetlCI 
. rtance of therapy and achieve a behavioral change in the patient towards better 1mpo 
persistence. 
LIMITATIONS 
Several limitations to this study can be described. Regarding the dataset used, 
patients may fill their prescriptions from pharmacies outside the HMO network and 
thus will not be captured. This, however, is unlikely, since the drugs were provided at 
discounted prices for patients in these pharmacies, and the assumption that patients fill 
most prescriptions within the pharmacy system under study has been confirmed in one 
HMO and 2 Veterans Affairs (VA) Medical Centers [61]. One study that tried to 
assess medication use outside the central pharmacy of the VA through a questionnaire 
found that 98.5% of patients reported using the central pharmacy as their only source 
of medication [62]. Also, fill ing the prescription is not identical to consuming the 
drug, yet patterns of prescription filling represent the most accurate way of estimating 
actual medication use in large populations [55]. We were unable to account for 
nonprescription drug use; for example, niacin could be obtained without a 
prescription, and we were unable to conduct medical chart reviews to validate the 
information attained from the computerized data. Thus, there could have been some 
misclassification of patients, but this would be of a non-differential type. It is not 
expected to be a major problem, as the data has been previously used in research. 
Continuous enrollment of the patients used in this study minimized selection bias as 
Well. 
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Characteristics of the population included may somewhat limit generalizability 
of results to the elderly population, but we are in need of "real world " LLA 
adherence studies in this age group [ 49] that consumes a relatively higher percentage 
of medications compared to other age groups [86, 106]. 
Other limitations include lack of comprehensive clinical data including lipid 
levels, and exact reason for discontinuation. We were unable to control for some 
potential confounders that have been reported to affect adherence like race [49, 117], 
socioeconomic status [123] , regimen complexity [89] , and perceived health [55, 89]. 
We also do not have information on income levels or coinsurances for our population 
cohort. We could not account for use of samples or hospitalizations during a follow up 
period, but our definition of 6 months without a drug somewhat limits the problem. It 
is difficult to obtain samples that cover such a period, and it is a long period for a 
continuous hospitalization. We did not control for some potential influencing 
conditions like stroke and potential statin side effects like myalgia, hepatitis, and 
rhabdomyolysis. These side effects, however, are not very common, myalgia occurs in 
1-5% of the statin users [131] , elevation in liver enzymes occurs in approximately I% 
of patients, while myopathy in approximately I in 1000 with monotherapy, and in very 
rare cases can lead to rhabdomyolysis [83]. 
Despite these limitations, we feel this research provides evidence that drug 
benefit plan options does not significantly affect discontinuation of LLAs, and that full 
coverage of prescription drugs does not guarantee persistence. 
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CONCLUSION 
Persistence to lipid-lowering therapy among elderly patients declined over time 
with the greatest drop during the first year. We did not find a significant association of 
drug benefit plan options with discontinuation. We noted statin use to be significantly 
associated with better persistence, while gender and previous hospitalization for CHO 
were no longer associated with persistence when controlling for other factors in the 
multivariate model. We also did not find an association with number of other 
medications 2:3 and age 2:70. 
Our findings suggest that adequate payment mechanisms are not enough to 
guarantee persistence. To achieve the desired benefit of therapy, Jong-term 
commitment to patient education, monitoring, and reinforcement with a 
multidisciplinary approach, including pharmacists, nurses, physicians and dieticians is 
warranted. 
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T hie 1 Characteristics of new users of lipid-lowering agents in an elderly 
p:pulation enrolled in a Medicare managed care health plan (n=322) 
Characteristic N O/o 
Gender Females 187 (58.1%) 
Males 135 (41.9%) 
Age Mean 70.4 
SD 4.5 
Plan type No coverage 12 (3.70%) 
$1000 maximum 108 (33.5%) 
Full coverage 202 (62.7%) 
Type of lipid-lowering agent prescribed Statin 188 (58.4%) 
Niacin 34 (10.6%) 
Fibrate 25 (7.80%) 
Bile acid sequestrant 75 (23 .3%) 
CHO diagnosis prior to prescription CHD diagnosis 159 (49.4%) 
No CHO diagnosis 163 (50.6%) 
Diabetes diagnosis prior to prescription OM diagnosis 71 (22.1 %) 
No DM diagnosis 251 (78.0%) 
Hypertension diagnosis prior to prescription HTN diagnosis 231 (71.7%) 
No HTN diagnosis 91 (28.3%) 
Number of other medication Mean 2.4 
SD 2.0 
.. 
SD=Standard dev1at1on, CHO= Coronary Heart Disease, DM=D1abetes Mel11tus, HTN=Hypertension 
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T hie 2 Coding and distribution of variables among new users of lipid-lowering 
a:ents in an elderly population enrolled in a Medicare managed care health plan 
(n=322) 
Variable Yes -1 * No-0* 
N O/o N O/o 
Plan type 202 (62.7%) 120 (37.3%) 
(full coverage) 
Gender (male) 135 .(41.9%) 187 (58.1%) 
Ag~70 161 (50.0%) 161 (50.0%) 
CHD diagnosis 159 (49.4%) 163 (50.6%) 
Diabetes diagnosis 71 (22.0%) 251 (78.0%) 
Hypertension diagnosis 231 (71.7%) 91 (28.3%) 
Number of other 125 (38.8%) 197 (61.2%) 
medication 2:3 
Statin user 188 (58.4%) 134 (41.6%) 
•c oded as I or 0 model. CDH= coronary heart disease 
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T ble 3 Discontinuation rates of new users of lipid-lowering agents at 6 months, 
1; months, and 18 months, stratified by patient characteristics in an elderly population enrolled in a Medicare managed care health plan (n=322) 
Variable Failed at Failed at Failed at Log-rank 
6 months 12 months 18 months Probability 
59 of322 109 of235 124of187 
118.3%1 _(46.4%1 166.3%1 
PlanJ!p_e: 0.3121 
Full coverage 31 of202 65of151 75of119 
(15.4%) (43.1%) (63.0%) 
Partial or no 28of120 44of84 49 of68 
covera_g_e (23.3%) (52.4%) (72.1%) 
Gender: 0.0078* 
male 16of135 35of88 39of71 
(11.9%) (39.8%) (54.9%) 
female 43of187 74of147 85of116 
(23.0%) (50.3%) (73.2%) 
A_g_e 0.2938 
2:70 36of161 58of116 66 of96 
(22.4%) (50.0%) (68.8%) 
<70 23of161 51 of 119 58of91 
(14.3%) (42.9%) (63.7%) 
CUD 0.0424* 
Diagnosis 
With CHD 25of159 45of110 52of88 
(15.7%) (40.9%) (59.1 %) 
oCHD 34of163 64of125 72 of99 
(20.9%) (51.2%) (72.7%) 
Diabetes 0.1011 
diagnosis 
With 8 of71 18 of 46 20of34 
diabetes (11 .3%) (39.1%) (58.8%) 
No diabetes 51 of251 91of189 104of153 
(20.3%) (48.1 %) (68.0%) 
Hypertension 0.2727 t-!1i~nosis 
With 43 of231 83of177 96of144 
1-~ertension (18.6%) (46.9%) (66.7%) N-o 
l!!n!_ertension 
16of91 26 of 58 28 of 43 
(17.6%) (44.8%) (65.1%) 
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Table 3 continued 
Variable Failed at Failed at Failed at Log-rank 
6 months 12 months 18 months Probability 
59of322 109 of235 124of187 
(18.3°/'!l_ _{_46.4%1 _(66.3%1 
Number of 0.3694 
other 
medications 
~3 27of125 46 of93 51of74 (21:6%) (49.5%) (68.9%) 
0-2 32of197 63of142 73of113 
(16.2%) (44.3%) (64.6%) 
Statin use 0.0004* 
Not user 32of134 61of 111 68 of 88 
(23.9%) (55.0%) (77.3%) 
User 27of188 48of124 56 of99 
(14.4%) (38.7%) (56.6%) 
*Stgmficant result p<0.05, CHD=Coronary Heart Disease 
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Table 4 Testing of the no interaction assumption for the stratification variable 
hypertension 
Model -2L 
full model 1196.272 
(with interaction terms for hypertension) 
Reduced model 1200.259 
Difference=1200.295-1196.272- 3.987, Not significant at df=7, 
chi-square=l 4.07, (0.5<p<O. 9) 
Table 5 Interaction assessment for variables included in the multivariate survival 
analysis model by the chunk test 
Model 
-2L 
3ways, 2ways, ls (full model) 1178.199 
2ways and ls (reduced+ 2ways) 1195.211 
1 s (reduced model) 1200.259 
Differences: 1195.211-1178.199= 17.012, Not significant at df=15 , 
chi-square=25, (0.1 <p<0.5) 
1200.295-1195.211 =5 .084, Not significant at df=6, 
chi-square=l2.59, (0.5<p<0.9) 
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T ble 6 Multivariate survival analysis model for new users of lipid-lowering 
a:ents in an elderly population enrolled in a Medicare managed care health plan 
(n=322) 
Variable 8 HR - e-rr Confidence interval Probability 
Plan -0.13143 0.877 0.610-1.260 0.4777 
Gender -0. 38646 0.679 0.458-1.007 0.0542 
Age 0.07065 1.073 0.745-1.547 0.7048 
CHD -0. 22617 0.798 0.549-1.160 0.2363 
Di~osis 
Diabetes -0. 35411 0.702 0.434-1.135 0.1490 
Diag_nosis 
#of Other 0.20606 1.229 0.833-1.812 0.2983 
medications 
Statin use -0.62378 0.536 0.375-0.766 0.0006 
•Significant result p<0.05, HR=Hazard ratio, CHO= Coronary Heart Disease 
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T hie 7 Confounding assessment for the multivariate survival analysis model of 
n:w users of lipid-lowering agents in an elderly population enrolled in a 
Medicare managed care health plan (n=322) 
Model 8 HR-e-u- Confidence interval Probability 
Full -0.13143 0.877 0.610-1.260 0.4777 
~ 
Full-gender -0.14542 0.865 0.601 -1.243 0.4328 
Full- age -0.13375 0.875 0.609-1 .257 0.4698 
Full-CHD - 0.13173 0.877 0.610-1.259 0.4760 
di~osis 
Full-Diabetes -0.14740 0.863 0.601-1.239 0.4250 
dil!S_nosis 
Full-#of other -.0.12280 0.884 0.616-1.270 0.5063 
medications 
Full-statin use - 0.14870 0.862 0.600-1.23 8 0.4208 
CHD=Coronary Heart Disease 
Table 8 Changes in hazards ratio with different control variables in the survival 
analysis model for new users of lipid-lowering agents in an elderly population 
enrolled in a Medicare managed care health plan (n=322) 
Model 8 HR=eT Confidence interval Probability 
Controlled for 
-0.13143 0.877 0.610-1.260 0.4777 
all variables 
Controlled for 
-0.16087 0.851 0.594-1 .221 0.3820 
statin use 
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Figure 1 Adjusted survival curves fo.r members of the full drug benefit 
plan and members of the $1~~0 maxn~um or no drug ben~fit plan in an elderly 
population of new users of hp1d-lowermg agents enrolled m a Medicare 
managed care health plan stratified by hypertension (n=322) 
Plot of S1*time. Symbol is value of plan. 
1.0 0 
0.9 
s 
u 
r 
v 
i 
v 
0 0.8 
r 
F 
u 
n 
c 
t 0.7 
i 
0 
n 
E 
s 
t 0.6 
i 
II 
a 
t 
e 
0.5 
0.4 
0 100 
1 11 
0 011 
0 0 111 
000 01 
00011 
0011 
00111 
001 1 
0 01 
0 0111 1 
0 0 0 
00 1 
000 1 
00 101 
0 11 
0 00 11 
0 1 
0 
00 
0 0 
200 300 400 
NOTE: 42 obs hidden time 
88 
0 
0 
0 
0 
0 0 
0 
500 600 
0 
Figure 2 Adjusted survival curves for members of the full drug benefit 
plan and members of the $1000 maximum or no drug benefit plan among 
hypertensive patients in an elderly population of new users of lipid-lowering 
agents enrolled in a Medicare managed care health plan (n=322) 
Plot of S11*time. Symbol is value of plan. 
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Figure 3 Adjusted survival curves for members of the full drug benefit 
plan and mem~ers of !he $1?00 maximum or no ~rug benefit plan among 
non-hypertensive patients m an elderly populatwn of new users of lipid 
lowering agents enrolled in a Medicare managed care health plan (n=322) 
Plot of S12*time . Symbol is value of plan. 
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Predictors of prescriber's choice among three statins: Influence of d rug benefit 
plan option. 
ABSTRACT 
Background Many health maintenance organizations (HMOs) have implemented 
programs providing varying degrees of annual drug coverage for Medicare 
beneficiaries enrolled in their plans. The unintended effects of such policies are 
important to consider. The beneficial effects of the statins class of dyslipidemic agents 
are widely documented. Fluvastatin can reduce low-density lipoprotein cholesterol 
(LDL-C) by 20-30%, which is enough to achieve the National Cholesterol Education 
Program (NCEP) target in most patients with high cholesterol and is the most cost-
effective in this range of LDL-C reduction. When a higher degree of cholesterol 
reduction is required other, more expensive, statins may be more appropriate. 
Objective To determine the effect of drug plan benefit options among elderly 
patients enrolled in managed care on the type of statin prescribed based on their 
relative cost. 
Methods A retrospective cohort study using 484 older adult members in a 
Massachusetts HMO who were prescribed a statin between September 1, 1994 and 
June 30, 1996 and who had no prior dispensing during the previous one year prior to 
September 1, 1994. 
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Logistic regression analysis was used to examine differences in type of statin 
prescribed between different drug benefit plans controlling for potential confounding 
effects of patient sex, age ?:..70, hospitalization for CHD prior to initial prescription, 
hypertension or diabetes mellitus diagnoses prior to initial prescription, and physician 
prescriber specialty. 
Results There was no significant association between the drug benefit plan 
option and statin type prescribed (OR=0.654; CI=0.3 76-1.139; p=0.1335) after 
controlling for potential confounders. There were no significant associations with 
other predictor variables as well. 
Conclusions Among the 3 on-formulary statin drugs available for prescribing 
(pravastatin, lovastatin and fluvastatin) , fluvastatin was the most widely prescribed. 
The results demonstrated that the drug benefit plan options did not affect the selection 
among statin drugs, based upon their relative cost. Further investigation using initial 
lipid levels is needed to investigate whether the more expensive drugs are being used 
in patients in need of further lowering of LDL-C beyond the capacity of fluvastatin , 
and that target cholesterol levels are being achieved among all patients to gain the 
potential benefit of these drugs. 
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BACKGROUND 
High cholesterol, specifically elevated low-density lipoprotein cholesterol 
(LDL-C), is a major cause of Coronary Heart Disease (CHO) [1-4], a link that was 
first made by the Framingham Heart Study [5]. Despite marked declines in mortality 
during this century [6-8], CHD continues to be the leading cause of death among the 
US population [9-1 1] and worldwide [10, 12]. Cardiovascular disease accounts for 
950,000 deaths annually in the US including 460,000 from CHD [9] . Eight-five 
percent of those who die from CHD are 65 years of age or older [9] . In 1990, there 
were 489,171 deaths attributed to CHD [6] , and 675,000 patients were discharged 
from US hospitals with a primary diagnosis of myocardial infarction [13]. 
Hospitalization for CHD continues to increase [7]. The prevalence of nonfatal CHD 
among US adults aged 40 and above was reported to be 11.8% [11]. It remains an 
important disease with significant burden. Estimated yearly costs of CHD for medical 
treatment and lost wages in the US range between $50 billion and $100 bill ion [2, 
9,14]. 
Currently, the American Heart Association estimates that 70 million adults in 
the US have total cholesterol levels>200mg/dl, and that at least 40% of these 
individuals have cholesterol levels in excess of 240mg/dl [9, 15]. The number of adults 
eligible for lipid modifying therapy was recently increased in the NCEP A TPIII 
guidelines to more than 65 million [3 , 15]. 
Statin drugs have assumed a major role in the treatment of LDL-C elevations. 
They are reversible inhibitors of HMG-CoA reductase. By inhibiting the rate-limiting 
step in cholesterol biosynthesis, these drugs reduce intracellular cholesterol stores. 
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Increased numbers of LDL receptors are then generated, thereby restoring intracellular 
cholesterol homeostasis and accelerating clearance of LDL-C from the plasma [ 16, 
17). 
The beneficial effects of cholesterol-lowering using these drugs are well 
documented through five landmark trials showing reductions in cardiovascular events 
in a diversity of patient populations, representing the continuum of individuals at risk 
for CHO [I 8]. The Scandinavian Simvastatin Survival Study ( 4S) [ 19] demonstrated 
improved survival and fewer cardiovascular events in hyperlipidemic CHO patients. 
The Cholesterol and Recurrent Events (CARE) [20] and the Long-term Intervention 
with Pravastatin in Ischemic Disease (LIPID) [21] extended the benefits to CHD 
patients with average cholesterol levels. In patients without CHD, evidence of benefit 
is provided by high risk primary prevention in men without a history of myocardial 
infarction (Ml) who were treated with pravastatin and diet in the West of Scotland 
Coronary Prevention Study (WOSCOPS) [22] , and with low and moderate risk 
primary prevention in men and women with below average high density lipoprotein 
cholesterol (HDL-C) levels treated with lovastatin and diet in the Air Force Texas 
Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS) [23] that extended 
the benefits to a substantial portion of the population. 
A meta-analysis by Gould et al. [ 1] reinforced the beneficial effects of these 
agents. It showed that the reduction of CHD and total mortality by LLAs could be 
explained by their lipid-lowering ability. The declines in CHD mortality this century 
[6-81 can in large part be explained by the improvement in treatments and secondary 
Prevention of MI [7]. 
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Statins are the most widely prescribed lipid-lowering agents (24-28]. They are 
recommended as first-line agents when drugs are indicated to achieve treatment goals 
[3, 27, 29, 30]. They are the most effective in reducing LDL-C, and the best tolerated 
among LLAs (26, 29, 30] . 
During the 1990s, increasing numbers of Medicare beneficiaries were 
becoming enrolled in managed care plans. Between 1989 and 1994, the HMO share of 
Medicare almost doubled (31]. In 1997, managed care enrolled 14.9% of the Medicare 
population (5.6 million) (32] , and in 2000, about 16% of Medicare patients were 
enrolled in Medicare plans associated with HMOs (33]. These differ from traditional 
Medicare plans in that the enrollees receive their coverage from the HMO rather than 
individual providers in private practice (33]. 
The growth in medical care expenditures is an important issue. The cost of 
pharmaceuticals has been reported to be among the fastest-rising components of 
healthcare costs, with a 17.3% increase in national expenditures for prescription drugs 
from 1999 to 2000 (34]. Spending on prescription drugs has increased at double-digit 
rates for the past decade and is now the third largest component of healthcare 
expenditures behind hospital care and physician services (35] . Pol icy responses have 
included limits on prescription costs, restriction on the supply of healthcare, and 
shifting of the financial risk to providers and beneficiaries (36-3 8] . Patient cost-
sharing through deductibles, coinsurance, and co-payments is one technique 
increasingly being used to contain medical costs in general, and prescription costs in 
Particular, to deter patients from unnecessary use (36-39]. The unintended effects of 
such policies are important to consider. There is a concern that necessary utilization 
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could be reduced, which may in turn increase the risk of adverse health consequences 
and resulting costs [34, 36-38, 40-42]. Cost-sharing does not affect everyone equally; 
those with small incomes, like many older adults are more likely to reduce use than 
those with higher incomes [43]. Low income populations appear to be sensitive to 
drug co-payments as low as 10-15% of average prescription expenses, with declines of 
5-10% observed in drug utilization [ 44]. Research has shown that Medicare patients 
who lack coverage receive fewer prescription medications than those with coverage 
[41 , 45, 46]. Other studies have shown the negative effect ofreducing drug coverage 
among the poor elderly and the consequences of inadequate coverage for older adults 
receiving medications that can prevent serious adverse health consequences [34, 47] . 
From January 1994 to December 1998, older adult members in an HMO in 
central Massachusetts were able to choose among 3 drug benefit plans: full drug 
coverage, a drug benefit plan with a maximum of $1000/year in coverage, and no drug 
benefit plan. Our objective was to examine the effect of this policy on the type of 
statin prescribed based on its price. Eighty-five percent of 132 physicians surveyed in 
eastern Massachusetts reported that inability to afford medication was a problem for 
some of their patients [48], and physicians may respond to the economic needs of their 
patients when prescribing drugs [ 49]. 
There are currently 5 available statins in the market: atorvastatin, fluvastatin, 
lovastatin, pravastatin, and simvastatin [50]. Although studies have indicated that 
fluvastatin on a mg to mg basis is less potent than other statins in reducing LDL-C 
[5l-53], it has been shown to reduce LDL-C by 20-30% [50, 51 , 54]- which is enough 
to achieve the National Cholesterol Education program (NCEP) target LDL-C in most 
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patients with high cholesterol [2, 3]. Priced at 40% lower than other statins, based on 
the annual wholesale cost of therapy per I% reduction of LDL-C [54, 55] , it is the 
most cost-effective in this range of LDL-C reduction [ 17, 53-56]. In high-risk patients, 
not the majority, when a higher degree of cholesterol reduction is required [2, 3], 
higher potency statins- sirnvastatin [17, 56] and atorvastatin [56]- appear to be more 
appropriate. 
In a study assessing the impact of switching from simvastatin to fluvastatin in 
an attempt to curb rising pharmaceutical cost after reference pricing was introduced in 
New Zealand [57] , there was a significant increase in cholesterol, LDL-C and 
triglycerides (p<O.O 1 ). The elevation was less pronounced when higher incremental 
doses of fluvastatin were used, so the lipid elevation relates to both lesser potency of 
fluvastatin and under-dosing. This was in a patient population requiring more than 
30% reduction in LDL-C to reach therapeutic goals (eligible for subsidized statin 
therapy). In such high-risk populations, significant lipid elevations may conceivably 
produce excess vascular events. Sub-therapeutic treatment may prove more costly than 
savings from reference pricing [57] . 
Prescribing of more expensive drugs in the more comprehensive drug benefit 
plans with small or no increase in therapeutic benefit may cause an unnecessary rise in 
cost. At the same time, optimal LDL-C reduction may not be achieved in high-risk 
patients if cheaper drugs are prescribed because of the drug benefit option, and 
prescribing less expensive but lower potency agents may be more costly than savings 
in the price of the drug in the long run. This study examined the implications of drug 
benefit plan options among Medicare beneficiaries enrolled in managed care on the 
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type of statin drug prescribed. We hypothesized that members of full coverage drug 
benefit plan were prescribed the higher priced statins more often than members of the 
$1000 maximum or no coverage plan members. 
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METHODS 
Data source and study population 
This research is a retrospective cohort study among older adult enrollees 
(Medicare beneficiaries) of an HMO operating in central Massachusetts, who were 
continuously enrolled in the plan during the period of July 1, 1993 - June 30, 1996, 
and were prescribed an LLA. These members were able to choose among 3 drug 
benefit options starting January 1, 1994: full coverage for prescription drugs, a 
maximum of $1000/year in coverage, or no drug coverage. Those selecting full 
coverage paid an additional premium of $72.50/month ($ 870/year). Those with a 
$1000 maximum coverage paid an additional $39 .16/month ($469 .92/year). Those 
without coverage paid no additional premium. 
Information on demographic characteristics, drug benefit plan type, 
prescriptions, ambulatory visits, hospitalization, and diagnoses was available for this 
population cohort. The population cohort was comprised of 2229 members. We 
deleted 325 members who switched from the original plan chosen on January 1, 1994, 
since we were unable to explore the effects of the type of drug benefit as a main 
predictor of the type of statin in these individuals. Of those, 251 (77.2%) switched 
from the full coverage plan, 61 (18.8%) from the $1000 maximum plan, and 13 (4.0%) 
from the no coverage plan. The final plans chosen by these patients were the ful I 
coverage plan in 89 patients (27.4%), the $1000 maximum plan in 186 (57.2%), and 
the no coverage plan in 50 (15.4%). 
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We then identified patients with a statin prescription between September 1, 
I 994 and June 30, 1996 among individuals with no prior dispensing of statin drugs in 
the one-year period before September 1, 1994, in order to identify relatively new users 
of statins. The definition of new users has been used in previous research [58, 59]. 
September 1, 1994 was chosen as a starting date because it is the date that fluvastatin 
was added to the HMO formulary. 
The dependent variable in the analysis was the type of statin drug received 
categorized into 2 groups based upon expense, pravastatin and lovastatin in one group 
as the more expensive drugs, and fluvastatin in the other group as the less expensive 
type. These 3 statins were the only ones available in the HMO formulary at the time of 
the study. Pravastatin and fluvastatin were preferred drugs in the formulary during that 
time period. Our main predictor of statin-prescribing patterns was type of drug benefit 
plan option. Other covariate predictors included age, gender, prescriber specialty, 
previous hospitalization for CHD, diabetes, and hypertension. These comorbidities 
were included since they are among the risk factors for CHD in the NCEP A TPII 
guidelines [2]. Age was categorized into two groups (below 70 years and 70 years or 
older). 
A patient was considered to have CHD if there was a hospitalization for CHO 
or a diagnosis for CHD (ICD-9 code= 410-414) prior to the statin prescription or 
during the one year prior to the study period. Patients with a diabetes diagnosis (ICD-9 
code=250) prior to the statin prescription or during the one year prior to the study date 
were labeled diabetic, and patients with a hypertension diagnosis (I CD-9 code= 401-
405) prior to the statin prescription or during the one year prior to the study date were 
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regarded as having hypertension. Finally, physician prescriber specialty was 
categorized into cardiologists and noncardiologists. 
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Statistical analyses 
Descriptive statistics were used to determine various patient characteristics. 
parametric assessment of age was carried out to examine the linearity of the 
association of age with the dependent variable. 
Bivariate analyses were used to assess the relationship between different 
independent variables and the dependent variable through chi-square analyses. Then, 
logistic regression was carried out to examine the association of each independent 
variable with the dependent variable separately. Results were presented as odds ratios 
with 95% confidence intervals. 
Co-linearity between various variables in the model was tested utilizing SAS 
proc corr. as suggested by Delwiche and Slaughter (60], to give correlation 
coefficients described by Johnson and Bhattacharyya (61]. 
Interaction assessment using the chunk test as described by Kleinbaum (62] 
calculated the difference between - 2L statistics of the full and reduced models. The 
full model has interaction terms while the reduced does not. Testing for significance 
was carried out using chi-square distribution with degrees of freedom equal to the 
number of interaction terms (difference in terms between the 2 models). A difference 
in - 2L value that was less than the chi-square statistic indicated no significant 
interaction. In case of significance (p<0.05), further evaluation of each of the 
interaction terms was carried out, and interaction terms with probabilities of more than 
1 % were dropped from the subsequent multivariate model. 
A multivariate logistic model with all independent variables and the outcome 
Variable was then formulated. Potential confounding was addressed by removing each 
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variable alone from the model and assessing the effect on the parameter estimate of 
the main predictor variable. Statistical significance was set at p<0.05, and the 
estimates were reflected by a 95% confidence interval. All statistical analysis was 
carried out using SAS statistical package version 8.1. 
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RESULTS 
Descriptive statistics 
A total of 484 patients met our inclusion criteria and were selected for the 
study. The mean age of these patients was 70.7 years of age. There were more female 
patients (n=287; 59.3%) than males (n=l 97; 40.7%) in our study population. 
More than half of the patients were covered by the full coverage drug benefit 
plan (n=320; 66.1 %), 30.4% by the partial coverage plan (n=147), and a small 
percentage by the no coverage drug benefit plan (n= l 7; 3.5%). Most of the 
prescriptions were written by internal medicine physicians (n=380; 78.5%). 
Cardiologists accounted for 7.9% (n=38) of the prescriptions, other specialties for 
12.8% (n=62), and we could not determine the specialty of the prescriber for four 
(0.8%) of our patient population. 
Approximately half of this patient population was hospitalized for CHO prior 
to the initial LLA prescription (n=243; 50.2%), 24.2% had a diabetes diagnosis prior 
to the initial prescription (n=l 17), and most had a hypertension diagnosis prior to the 
initial prescription (n=340; 70.3%). Fluvastatin was the most prescribed statin 
accounting for 87.4% (n=423) of the prescriptions. Pravastatin accounted for 9.3% 
(n=45) of the prescriptions, while lovastatin for 3 .3% (n= 16). This information is 
Summarized in Table 1. 
The coding of various variables in subsequent bivariate and multivariate 
analyses is presented in Table 2. Because of the low percentage of patients in the no 
coverage plan benefit, drug benefit plan type was further categorized as full coverage 
(n=320; 66.1 %) versus partial or no coverage (n=164; 33.9%). Physician prescriber 
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specialty was categorized further into cardiologists (n=38; 7.9%) and noncardiologists 
(n==446; 92.2% ). Age was converted into a dichotomous variable with age below 70 
years in one group (n=22 l ; 45 .7%), and 70 years or older in the other group (n=263 ; 
S4.3%), based on a parametric assessment. Statin use, the outcome variable, was 
categorized into higher-priced statin (lovastatin and pravastatin) in one group (n=61 ; 
12.6%) and lower-priced statin (tluvastatin) in the other (n=423 ; 87.4%). 
Results of the bivariate chi-square analyses are presented in Table 3. Our 
main predictor variable, plan type, was not found to be significantly associated with 
the outcome variable of statin type prescribed (p=0.1230). The more expensive statins 
were prescribed in 10.9% of those with full coverage and 15.9% of partial or no 
coverage members. There were no significant associations between the other 
independent variables and the outcome variable as well. 
In the univarite logistic regression model, the drug benefit plan type was also 
not significantly associated with the type of statin prescribed (OR=0.65 ; CI=0.377-
1.126; p=0.1247). No significant associations were found between other independent 
variables and the outcome variable. These results are shown in Table 4. 
Table 5 summarizes results of interaction assessment for the variables that 
were to be included in the model with the main predictor variable of plan type. No 
significant 3-way or 2-way interactions existed. 
The multivariate logistic regression model showed no significant association 
between the drug benefit plan type and the outcome variable of statin drug type 
prescribed (OR=0.65; CI=0.376-1 .139; p=0.1335). Other covariates- gender, age, 
prescriber specialty, CHO hospitalization prior to prescription, diabetes diagnosis prior 
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to prescription, and hypertension diagnosis prior to prescription- were also not 
significantly associated with the outcome variable. These results are presented in 
Table 6. 
Results of confounding assessment are presented in Table 7. None of the 
variables removed caused major changes in the parameter estimate of the main 
predictor variable. 
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DISCUSSION 
Administrative databases provide a cost-effective alternative to post-marketing 
clinical trials in a real world setting [63 , 64] , and provide a useful source of 
pharmacoepidemiologic assessments of drug utilization. Automated databases can be 
used to assess prescribing patterns and trends of drug use [65-67] , impact of policies 
[68] , and drug adherence [58, 59, 69-72]. 
In this study, we used data from an HMO operating in Massachusetts to study 
the effect of drug benefit plan options on the type of statin drug prescribed among new 
older adult users. 
The study population had a high prevalence of CHD (50.2%), diabetes 
(24.2%), and hypertension (70.3%) compared to the reported prevalences in the 
general population [11, 73 , 74] , which is understandable considering it is a population 
of older adults being treated for hypercholesterolemia. Most patients also chose the 
full coverage benefit plan (66.1 %), which can be explained by the higher drug use in 
this age group compared to younger patients [75, 76]. 
Most prescriptions were written by internists (78.5%), which is consistent 
with previous reports of internists having more patients on LLAs compared to 
cardiologists and family physicians [25, 77]. 
The majority of our patients (87.4%) were on fluvastatin . Fluvastatin has been 
shown to reduce LDL-C by 20-30% in doses 20-80mg [50, 51 , 54], which is enough to 
achieve the NCEP target LDL-C in most patients with high cholesterol [2, 3] . 
Furthermore, Jacocot et al. demonstrated that fluvastatin 40mg provided more LDL-C 
reduction (with 30.4% reduction) than pravastatin 20mg (with 26.4% reduction) after 
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16 weeks of treatment. Priced at 40% lower than other statins, based on the annual 
wholesale cost of therapy per 1 % reduction of LDL-C [54, 55], it is the most cost-
effective in this range of LDL-C reduction [17, 53-56]. The HMO also had a 
negotiated price that was even lower for fluvastatin, making the price difference with 
other statins even higher. 
Furthermore, the majority of prescriptions for statin drugs are written for low 
doses that produce moderate levels of LDL-C reductions. A 1993 audit [78] of usage 
ofHMG-CoA reductase inhibitors showed that in 72% of instances, lovastatin was 
written in doses not exceeding 20mg daily (expected LDL reduction<24%), 
simvastatin in 64% of the cases was used in doses not exceeding l Omg/day (expected 
LDL-C reduction <28%), and pravastatin in 88% of the cases was used in doses not 
exceeding 20mg daily (expected LDL-C reduction <25%) [56]. Another study in 
South Africa reported patients on pravatstatin to be using a relatively low dose 
(average =12.5mg; SD= 5.1) [28] . These drugs are most commonly used in doses that 
reduce LDL-C by 20-30%, the range where fluvastatin is the most cost effective [17, 
53-56, 79]. 
An association between insurance type and cost of drugs prescribed has been 
previously reported [49, 80], and patients who pay out of pocket have also been 
reported to receive lower cost drugs [46, 49, 80, 81]. Mott et al. reported that 
indemnity patients and uninsured were found to be dispensed brand names and generic 
drugs of lower cost compared to private third party and Medicaid patients, suggesting 
that physicians may respond to the economic needs of their patients when prescribing 
drugs [49] , as persistence with these medications [58, 72, 82, 83]- as well as inability 
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to afford them- [48, 84-86] is a concern. These studies, however, did not control for 
factors that may affect the price of product chosen, including demographic variables 
and patient comorbidities [46, 49] , and were not specific to statins [46, 49, 80]. The 
final choice among different agents is left to the clinical judgment of physicians [2, 3, 
27] 
In this study, the drug benefit plan type was not found to be significantly 
associated with the outcome variable of statin type prescribed in the chi-square 
(p=0.1230), bivariate logistic regression model, (OR=0.65; CI=0.377-1.126; 
p=0.1247) , or multivariate logistic regression model (OR=0.65; CI=0.376-1.139; 
p=0.1335). Although we did not have information on the initial LOL-C levels of our 
patients prior to the prescription or their exact target LDL-C level , we have controlled 
for risk factors that affect the target level LDL-C when possible in the multivariate 
model, which may to some extent be indicative of the amount of lowering needed. At 
the time of the study, NCEP A TPII [2] guidelines were available. Risk factors for 
CHD included age (2':.45 for men 2':.55 or premature menopause for women), family 
history of premature heart disease, current smoking, hypertension, low high-density 
lipoprotein cholesterol (<35mg/dl), and diabetes mellitus. Having 2 or more risk 
factors placed the patient in an intermediate risk group with target LOL-C of 
130mg/dl, while having CHO placed the patient in the highest risk group with target 
LDL-C of lOOmg/dl. The target levels and risk factors are presented in Table 8. We 
controlled for diabetes, hypertension, and CHO, prior to the prescription, as well as for 
age, gender, and physician prescriber specialty. None of these factors were found to be 
associated with the type of statin drugs prescribed in bivariate or multivariate analyses. 
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This is understandable with regard to diabetes and hypertension, since having either of 
these diseases does not place the patient in the highest risk group, even though 
diabetes in the more recent guidelines (NECP A TPIII) is considered a coronary heart 
disease risk-equivalent that lowers the target LDL-C to lOOmg/dl [3]. At the time of 
the study, that was not the case. As for CHD, we would expect that patients with CHO 
may need a higher percentage of lowering considering the lower target LDL-C of 
IOOmg/dl, but we cannot be sure ofthis, since information on the initial LDL-C must 
be known to determine the exact percentage of lowering needed. It could be that most 
of the CHD patients in this cohort did not need more than 30% lowering. Furthermore, 
fluvastatin dose can be increased further to 80 mg, providing better LDL-C reduction 
[53]. CHD patients on fluvastatin might have been receiving higher doses or they 
might have been receiving combination therapy for further lowering. Combination 
therapy is safe, effective, well-tolerated, and can achieve lipid reductions that exceed 
those observed with high dose monotherapy, since the combination employs two 
different classes with complimentary mechanisms of action to give an additive effect 
(87, 88]. 
Our results demonstrated that the drug benefit plan options selected by the 
patient did not affect the type of statin drug prescribed, whether it is the more 
expensive or less expensive type, after controlling for potential confounders. While it 
is desirable for physicians to take into consideration the financial abilities of their 
patients to improve persistence, it would not be advantageous to compromise the 
potential benefit of therapy. This is especially true because many patients are not 
achieving their target LDL-C levels, a problem which is more prominent among the 
127 
older adults [89, 90]. Further investigation with documented initial cholesterol levels 
would give a clearer understanding of whether the more expensive drugs are being 
used in patients in need of further lowering of LDL-C beyond the capacity of 
fluvastatin, and that target cholesterol levels are being achieved among all patients. 
LIMITATIONS 
Several limitations to this study can be described. Regarding the dataset used, 
patients may fill their prescriptions from pharmacies outside the HMO network and 
thus will not be captured as users of statin drugs. This, however, is unlikely, since the 
drugs were provided at discounted prices for patients in these pharmacies, and the 
assumption that patients fill most of prescriptions within the pharmacy system under 
study has been confirmed in one HMO and 2 Veterans Affairs (VA) Medical Centers 
[91]. One study that tried to assess medication use outside the central pharmacy of the 
VA through a questionnaire found that 98.5% of patients reported using the central 
pharmacy as their only source of medication [71] . Characteristics of the population 
included may somewhat limit generalizability of results to the general population. The 
drug dispensed may sometimes be different from that prescribed by the physician and 
we can only capture that dispensed. Using new users of drugs may somewhat limit this 
problem. 
We also have no information regarding incentives to physicians at the HMO 
for prescribing fluvastatin, the lowest priced drug and the most prescribed in this 
patient population, although we know that both fluvastatin and pravastatin were 
preferred drugs on the formulary. As with automated data, misclassification of patients 
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may have occurred, since we could not validate the information with medical charts, 
but would be of the nondifferential type. The data is relatively old, but it provides a 
unique opportunity to study the effect of drug benefit plan options and to compare 
changes in practice with the publication of recent guidelines, and with newer agents 
that were not on the formulary at the time of the study in a ' real world' setting. 
Other limitations include Jack of comprehensive clinical data including initial 
lipid levels. Such information would have allowed us to control for the exact amount 
of LDL-C lowering needed for the patients. Information on some potential 
confounders like family history of CHD and smoking status is also lacking. We also 
do not have information on income levels or coinsurances for our population cohort, 
and did not control for some potential influencing conditions like stroke. 
Despite these limitations we believe our study provided evidence showing the 
absence of a significant association between the drug benefit plan option selected by 
the patients and type of statin prescribed. 
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CONCLUSION 
Among the 3 on-formulary statin drugs available for prescribing 
(pravastatin, lovastatin and fluvastatin), fluvastatin was the most widely prescribed in 
this patient population. The results demonstrated that the drug benefit plan option did 
not affect choice among statins, whether it was the more expensive or less expensive 
type, after controlling for potential confounders including gender, age, physician 
prescriber specialty, CHD, diabetes, and hypertension diagnoses prior to the 
prescription. Further investigation with initial lipid levels is needed to determine 
whether more expensive drugs are being used in patients in need of further lowering of 
LDL-C beyond the capacity of fluvastatin, and whether target cholesterol levels are 
being achieved among all patients to gain the potential benefit of these drugs. 
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Table 1 Characteristics of new users of statin drugs in an elderly population 
enrolled in a Medicare managed care health plan (n=484) 
Characteristic N O/o 
Gender Females 287 (59.3%) 
Males 197 (40.7%) 
Age Mean 70.7 
SD 4.5 
Plan type No coverage 17 (3.50%) 
$1000 max 147 (30.4%) 
Full coverage 320 (66.1 %) 
Prescriber specialty Cardiology 38 (7.90%) 
Internal medicine 380 (78.5%) 
Others 62 (12.8%) 
Missing 4 (0.80%) 
CHD diagnosis prior to prescription CHD diagnosis 243 (50.2%) 
No CHD diagnosis 241 (49.8%) 
Diabetes diagnosis prior to prescription DM diagnosis 117 (24.2%) 
No DM diagnosis 367 (75.8%) 
Hypertension diagnosis prior to prescription HTN diagnosis 340 (70.3%) 
No HTN diagnosis 144 (29.8%) 
Statin drug prescribed Fluvastatin 423 (87.4%) 
Pravastain 45 (9.30%) 
Lovastatin 16 (3.30%) 
.. SD=Standard deviation, CHO= Coronary Heart Disease, DM=Diabetes Mellitus, HTN=Hypertension 
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Table 2 Coding and distribution of variables among new users of statin drugs in 
an elderly population enrolled in a Medicare managed care health plan (n=484) 
Variable Yes-1* No-0* 
Plan type 320 (66.l %) 164 (33.9%) 
(full coverage) 
Gender 197 (40.7%) 287 (59.3%) 
(male) 
Age 2:70 263 (54.3%) 221 (45.7%) 
Prescriber specialty 38 (7.9%) 446 (92.1 %) 
(cardiologist) 
CHO diagnosis 243 (50.2%) 241 (49.8%) 
Diabetes diagnosis 117 (24.2%) 367 (75.8%) 
Hypertension diagnosis 340 (70.3%) 144 (29.8%) 
Higher priced statin 61 (12.6%) 423 (87.4%) 
(pravastatin or 
lovastatin) 
*Coded as I or 0 m the logistic regression model. CDH= coronary heart disease 
132 
Table 3 Distribution of patients with regard to different variables and the 
outcome variable of statin drug type among new users of statin drugs in an 
elderly population enrolled in a Medicare managed care health plan (n=484) 
Lower priced Higher priced Total probability 
statin statin 
N=423 N=61 N=484 
J.87.40%) (12.60%) (100%) 
Plan Jn!._e 0.1230 
Full coverage 285 35 320 
O/o (89.0%) (10.9%) (100%) 
Partial I no 
coverage 138 26 164 
O/o (84.2%) (15.9%) (100%) 
Gender 0.8173 
Male 173 24 197 
O/o (87.8%) (12.2%) (100%) 
Female 250 37 287 
% (87.l %) (12.9%) (100%) 
Age 0.2894 
;?:70 226 37 263 
O/o (85.9%) (14.1%) (100%) 
<70 197 24 221 
% (89.l %) (10.9%) (100%) 
Prescriber 0.5376 
~ecia!_!y 
Cardiologist 32 6 38 
O/o (84.2%) (15.8%) (100%) 
Non-
cardiologist 391 55 446 
O/o (87.7%) (12.3%) (100%) 
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Table 3 continued 
,--- Lower Higher priced Total probability 
priced statin 
statin N=61 N=484 
N=423 (12.60%) (100%) 
_i87.40%l 
CHD diag_nosis 0.1410 
WithCHD 207 36 243 
O/o (85.2%) (14.8%) (100%) 
NoCHD 216 25 241 
O/o (89.6%) (10.4%) (100%) 
Diabetes 0.8114 
dia_g_nosis: 
With diabetes 103 14 117 
O/o (88.0%) (12.0%) (100%) 
No diabetes 320 47 367 
O/o (87.2%) (12.8%) (100%) 
Hypertension 0.2486 
diagnosis 
With 
hypertension 301 39 340 
% (88.5%) (11.5%) (100%) 
No 
hypertension 122 22 144 
% (84.7%) (15 .3%) (100%) 
CHO-Coronary Heart Disease 
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Table 4 Univariate logistic regression for new users of statin drugs in an elderly 
population enrolled in a Medicare managed care health plan (n=484) 
IV OR -e--u- Confidence interval Probability 
Plan type 0.652 0.377-1.126 0.1247 
o ==partial I no coverage 
t = full coverage 
Gender 0.973 0.541-1.623 0.8174 
O=female 
1 =male 
Age 1.344 0.777- 2.325 0.2906 
O= age <75 
l=Age >75 
Prescriber specialty 1.333 0.533- 3.334 0.5384 
O=noncardiologist 
1 = cardiologist 
CHD diagnosis 1.503 0.871-2.590 0.1429 
O=no CHD, 
l=with CHD 
Diabetes diagnosis 0.952 0.490-1.749 0.8115 
O=no diabetes, 
1 =with diabetes 
Hypertension Diagnosis 0.718 0.409-1.262 0.2499 
O=no hypertension 
1 =with hypertension 
OR- odds ratio. CHD=Coronary Heart Disease 
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Table 5 Interaction assessment for variables included in the multivariate logistic 
regression model by the chunk test 
Model -2L 
3ways, 2ways, 1 s (full model) 333 .231 
2ways and l s (reduced+ 2ways) 346.042 
Is (reduced model) 359.241 
Differences: 346.042-333.231 = 12.81 l , NS at df= l5, 
chi-square=25, (0.1 <p<0.5) 
359.241-346.042=13. l 99, at df=6, 
chi-square= 12.59 (0.025<p<0.5) 
Lowest probability for interaction term=O.O 149>0.01 
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Table 6 Multivariate logistic regression model for new users of statin drugs in an 
elderly population enrolled in a Medicare managed care health plan (n=484) 
.-Variable 8 OR - elf CI Probability 
Plan -0.4245 0.654 0.376- 1.139 0.1335 
Gender -0.2069 0.813 0.457-1.446 0.4810 
Age 0.2929 1.340 0.765- 2.349 0.3064 
Prescriber 0.1767 1.193 0.462-3.080 0.7150 
Spe_cialty 
CHD 0.4271 1.533 0.861-2. 729 0.1468 
Diagnosis 
Diabetes -0.0787 0.924 0.483-1. 768 0.8120 
Diagnosis 
OR=odds ratio, CI=Confidence Interval, CHD=Coronary Heart Disease 
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Table 7 Confounding assessment for the Multivariate logistic regression model of 
new users of statin drugs in an elderly population enrolled in a Medicare 
managed care health plan (n=484) 
Model 8 OR-e--ir CI Probability 
Full -0.4245 0.654 0.376- 1.139 0.1335 
Full-gender -0.4295 0.653 0.375-1.137 0.1321 
Full- age -0.4239 0.654 0.376-1.139 0.1337 
Full-Prescri her -0.4219 0.656 0.377-1.141 0.1357 
S_Q_ecialty 
Full-CHD -0.4030 0.668 0.385-1.161 0.1526 
Diagnosis 
Full-Diabetes -0.4246 0.654 0.3 76-1.139 0.1334 
Dia_B!losis 
Full-hypertension -0.4588 0.632 0.364-1.096 0.1024 
Diagnosis 
OR=odds ratio, CI=confidence Interval, CHD=Coronary Heart Disease 
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Table 8 Coronary heart disease risk groups based on Adult Treatment Panel 
11 treatment recommendations. 
Coronary LDL- cholesterol 
Heart Disease to initiate diet 
Risk Group mg/di 
Without CHD* 
and <2 risk factors* 
Without CHD * 
and with ~2 
risk factors* 
With CHD* 
~160mg/dl 
~130mg/dl 
> lOOmg/dl 
*CHD=Coronary heart disease. 
LDL -cholesterol 
to initiate drug 
mg/di 
~ 190mg/dl 
~160mg/dl 
~130mg/dl 
LDL -cholesterol 
goal mg/di 
<160mg/dl 
<130 mg/di 
:S100mg/dl 
* Positive risk factors for CHD include age (~45 for men ~55 or premature 
menopause for women), family history of premature heart disease, current 
smoking, hypertension, low high-density lipoprotein cholesterol ( <35mg/dl), and 
diabetes mellitus. High-density lipoprotein (~60mg/dl) is a negative risk factor. 
Source: Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults: Summary of the second report of National Cholesterol 
Education Program (NCEP) expert panel on detection evaluation and treatment of 
high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 
269:3015-3023. 
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Part 2 includes the following appendices: 
Appendix A. Background and significance 
Appendix B. Details of the methods 
Appendix C. Overview of major findings 
Appendix D. Kaplan Meier survival curves and log-log Kaplan Meier survival curves 
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APPENDIX A. BACKGROUND AND REVIEW OF THE PROBLEM 
The growth in medical care expenditures is an important issue. The cost of 
pharmaceuticals has been reported to be among the fastest-rising components of 
healthcare costs, with a 17.3% increase in national expenditures for prescription drugs 
from 1999 to 2000 [1 ]. Spending on prescription drugs has increased at double-digit 
rates for the past decade and is now the third largest component of healthcare 
expenditures behind hospital care and physician services [2]. Policy responses have 
included limits on prescription costs, restriction on the supply of healthcare, and 
shifting of the financial risk to providers and beneficiaries [3-5]. Patient cost-sharing 
through deductibles, coinsurance, and co-payments is one technique increasingly 
being used to contain medical costs in general , and prescription costs in particular, to 
deter patients from unnecessary use [3-6]. There is, however, a concern that necessary 
utilization could also be reduced, which may increase the risk of adverse health 
consequences and resulting costs [1 , 3-5, 7-9]. When the Medicaid program in New 
Hampshire placed a limit of 3 reimbursable medications that a patient could receive 
per month, there was a 30% drop in the number of prescriptions filled per month 
among 10,734 enrollees, and a reduction in the use of essential medications like 
insulin and antihypertensives [10] . This, in turn, increased the risk of nursing home 
admissions and overall healthcare costs [11] , since patients may simply shift the type 
of service sought to deal with the health problem [3] . Several other studies have 
reported a decrease in prescription filling due to cost-sharing [12-14]. Older adult 
patients are of particular concern since cost-sharing does not affect everyone equally; 
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those with small incomes, like many older adults, are more likely to reduce use than 
those with higher incomes [ 15] . 
The Medicare population is demographically different from the Medicaid 
population, and thus its response to such policies may differ. Research has shown, 
however; that Medicare patients who lack coverage receive fewer prescription 
medications than those with coverage [8, 16] and that medication restriction is 
common in older adults who lack prescription drug coverage [9]. Other studies have 
demonstrated the negative effect of reducing drug coverage among poor older adults 
and the consequences of inadequate coverage for the older adult patients receiving 
medications that can prevent serious adverse health consequences [ 1, 17]. 
Many health maintenance organizations (HMOs) have implemented programs 
providing varying degrees of annual drug coverage for Medicare beneficiaries enrolled 
in their plans. Older adult plan members in an HMO operating in Massachusetts were 
able to choose among 3 drug benefit options starting January 1, 1994: full coverage for 
prescription drugs, a maximum of $1000/year in coverage, or no drug coverage. This 
research looks into the effects of this policy on lipid-lowering agents (LLAs), a group 
of drugs of well-documented benefit for both primary [18-21] and secondary [22-26] 
prevention of coronary heart disease (CHD). 
Despite marked declines in mortality during this century [27-29], CHO 
continues to be the leading cause of death among the US population [30-32] and 
worldwide [31, 33]. Cardiovascular disease accounts for 950,000 deaths annually in 
the US, including 460,000 from CHD [30]. Eighty-five percent of those who die from 
CHO are 65 years of age or older [30]. In 1990, there were 489, 171 deaths attributed 
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to CHO [27] , and 675,000 patients were discharged from US hospitals with a primary 
diagnosis as myocardial infarction [34]. Hospitalization for CHO continues to increase 
[28]. The prevalence of nonfatal CHD among US adults aged 40 and above was 
reported to be 11.8% [32]. It remains an important disease with significant burden. 
Estimated yearly costs of CHO for medical treatment and lost wages in the US range 
between $50 billion and $100 billion [30, 35 , 36]. The aging population, increased 
prevalence of diabetes and hypertension, and growing number of overweight 
Americans can explain the persistence of CHD as the leading cause of death [37]. The 
declines from previous years can, in part, be explained by the improvement in 
treatments and secondary prevention of MI [28]. 
High cholesterol, specifically elevated low-density lipoprotein cholesterol 
(LOL-C), is a major cause of CHD [35, 37, 38, 39], a link that was first made by the 
Framingham Heart Study [40]. 
Twenty-eight percent of US adults over age 20 have hyperlipidemia that 
warrants treatment [41] , based on the National Health and Nutrition Examination 
Survey (NHANES) III phase 2 data (collected from 1991-1994) and the 1993 National 
Cholesterol Education Program (NCEP) recommendations that were the standard of 
practice at the time of the study [35]. 
Currently the American Heart Association estimates that 70 million adults in 
the US have total cholesterol levels>200mg/dl, and that at least 40% of these 
individuals have cholesterol levels in excess of 240mg/dl [30,42] . The number of 
adults eligible for lipid-modifying therapy was recently increased in the NCEP ATP 
III guidelines to more than 65 million [39, 42] . Furthermore, guidelines recognize that 
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the majority of these patients will require drug therapy to achieve target cholesterol 
levels goals [39, 43]. 
Currently, there are 4 major classes of LLAs in use: statins, bile-acid-binding 
resins, nicotinic acid, and fibrates [31 ]. The first objective of this research project was 
to describe LLA use among a group of Medicare beneficiaries enrolled in managed 
care with high cholesterol levels. We examined the LLAs prescribed during a one-year 
period and compared this utilization with various patient characteristics including 
gender, age group, prescriber specialty, comorbidities (CHD, diabetes, hypertension), 
and choice of drug benefit plan option. This was carried out for both new and 
prevalent users during the one- year period. The study provides insight into ' real 
world' patterns of LLA drug use and variation among sub-populations. 
The second objective of this research was to investigate the effects of the drug 
benefit plan options on the persistence of lipid-lowering therapy. 
Persistence of cholesterol-therapy is expected to be a problem, based on 
previous reports showing that compliance with drug therapy for chronic diseases is 
frequently sub-optimal [44] . The cumulative treatment discontinuation among long-
tenn regimens of all types is about 50% of patients at the first year [ 44-51 ], and there 
are no reasons for persistence in LLAs to be any different [44]- especially that 
hypercholesterolemia is a chronic condition that is perceived by the patient as having 
deleterious health consequences that are far in the future [52] . 
The public health importance of persistence for gaining a widespread benefit 
from LLA is emphasized by the dominance of atherosclerotic disease as the major 
cause of morbidity and mortality in the United States [27, 32, 34], and the efficacy of 
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cholesterol drugs in obtaining benefits in both primary [18-21] and secondary [22-26] 
prevention of CHD. The economical and widespread achievement of benefits depends 
on all risk-qualified patients obtaining a high level of persistence to these regimens of 
proven efficacy. Little is known about persistence to lipid-lowering therapy among 
older patients, since studies have preferentially enrolled younger patients or informed 
subjects they were being monitored, thus reducing generalizability of the results [53-
55]. 
Financial incentives have been shown to improve compliance in patients [56] . 
Eighty-five percent of 132 physicians surveyed in eastern Massachusetts reported that 
inability to afford medication was a problem for some of their patients [57]. Thirty-
eight of patients who discontinued their medication in a follow-up study one year after 
the conclusion of the 4S study, blamed acquisition costs [58]. Cost of medications was 
also found to be among factors contributing to noncompliance in the older adults [59]. 
Medicare patients who do not have prescription drug coverage face higher out of 
pocket expenditures and may not comply with their medications to save money [60]. 
Furthermore, Medicare beneficiaries with capped prescriptions have been 
shown to take steps to decrease their out of pocket prescription costs, including taking 
samples from physicians, taking less than the prescribed dose, and discontinuing the 
prescribed medication [61]. Still, research in older adult patients taking specifically 
LLAs has shown high discontinuation rates in patients with drug coverage [ 48, 55, 62, 
63]. A study in British Columbia, where there are various levels of coverage provided 
by the provincial government, found no significant difference between adherent and 
non-adherent patients with respect to type of provincial coverage [64]. This research 
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explored the effects of drug benefit plans chosen among Medicare beneficiaries 
enrolled in managed care on persistence of LLAs. We hypothesized that patients with 
full coverage have lower discontinuation rates compared to those with partial or no 
coverage. 
The third objective of this research was to explore the effects of the drug 
benefit plan options on the type of statin drug prescribed. 
There are currently 5 available statins in the market: atorvastatin, fluvastatin, 
Iovastatin, pravastatin, and simvastatin [65]. Although studies have indicated that 
fluvastatin on a mg to mg basis is less potent than other statins in reducing LDL-C 
[66-68], it has been shown to reduce LDL-C by 20-30% in doses 20-80mg [65, 66, 69] 
which is enough to achieve the NCEP target LDL-C in most patients with high 
cholesterol [35, 39]. Jacocot et al. demonstrated that fluvastatin 40 mg provided more 
LDL-C reduction (with 30.4% reduction) than pravastatin 20mg (with 26.4% 
reduction) after 16 weeks of treatment. The fluvastatin dose can be increased further to 
80mg, providing better LDLC reduction [68]. Priced at 40% lower than other statins, 
based on the annual wholesale cost of therapy per 1% reduction ofLDL-C [69, 70], it 
is the most cost-effective in this range ofLDL-C reduction [68-72]. For higher degrees 
of LDL reduction, simvastatin [71, 72] and atorvastatin are more effective [72]. 
Furthermore, the majority of prescriptions for statin drugs are written for low 
doses that produce moderate levels of LDL-C reductions. A 1993 audit [73] of usage 
ofHMG-Co-A reductase inhibitors showed that in 72% of instances, lovastatin was 
written in doses not exceeding 20mg daily (expected LDL reduction<24%), 
simvastatin in 64% of the cases was used in doses not exceeding 1 Omg/day (expected 
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LDL-C reduction <28%), and pravastatin in 88% of the cases was used in doses not 
exceeding 20mg daily (expected LDL-C reduction <25%) [72]. Thus, these drugs are 
most commonly used in doses that reduce LDL-C by 20-30%, the range where 
fluvastatin is the most cost effective [68-72, 74]. 
Still, in high-risk patients, not the majority, when a higher degree of 
cholesterol reduction is required, higher potency statins appear to be more appropriate 
[71 , 72] . In a study assessing the impact of switching from simvastatin to fluvastatin in 
an attempt to curb rising pharmaceutical costs after reference pricing was introduced 
in New Zealand [75] , there was a significant increase in cholesterol, LDL-C and TGs 
(p<O.O l ). The elevation was less pronounced when higher incremental doses of 
tluvastatin were used, so the lipid elevation relates to both lesser potency of fluvastatin 
and under-dosing. In high-risk populations, significant lipid elevations may 
conceivably produce excess vascular events. Sub-therapeutic treatment may prove 
more costly than savings from reference pricing [75]. 
An association between insurance type and costs of drugs prescribed has been 
previously reported by Mott et al. [76]. Private third party and indemnity prescriptions 
were more likely to be dispensed with brand name drugs compared to Medicaid and 
the uninsured. Also, indemnity patients and uninsured were found to be dispensed 
brand names and generic drugs of lower cost, suggesting that physicians may respond 
to the economic needs of their patients when prescribing drugs [76]. 
Patients who pay out of pocket have also been reported to receive lower cost 
drugs [77]. We examined the effects of drug benefit plan options on type of statin drug 
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prescribed and hypothesized that more expensive statins are more prescribed in the 
full coverage plan compared to the other two plans. 
In sum, this research explored the effects of various degrees of annual drug 
coverage on prescribing and persistence ofLLAs in a group of Medicare beneficiaries 
under managed care in a real world setting. It provides insight into the effects of such 
policies in this fastest growing age group [78] , why target cholesterol levels are not 
always met, and factors affecting persistence as well as choice of LLA. It also gives 
rise to more questions in need of further investigations, like the effects in specific sub-
populations such as those with higher risk and in need of relatively higher degrees of 
cholesterol lowering. 
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APPENDIX B DETAILS OF THE METHODS 
Data source and patient population 
Data for research were provided by an HMO in central Massachusetts to the 
Department of Applied Pharmaceutical Sciences at the University of Rhode Island. 
Data consisted of several SAS datasets including demographic data, enrollment data, 
diagnosis data, referral data, and pharmacy data, with a unique patient identifier for 
linkage. In addition, one excel sheet for the physician specialties, and a drug 
dictionary that gave NDC codes of different drugs were provided. The data had 
information for 2229 patients who were continuously enrolled between July 1, 1993 
and June 30, 1996, and had a prescription for an LLA. 
The demographic data had the following variables: 
ID: Unique patient identifier. 
DOB: Patient date of birth; in mm/dd/yy format. 
SEX: Male or female, (included as 'M" or ' F' ). 
The enrollment data had 4956 lines for the 2229 patients and the following 
variables: 
ID: Unique patient identifier. 
EFFDATE: The effective date of starting enrollment in mm/dd/yy format 
PLANTYPE: Drug coverage type with ' X' for full coverage, 'N ' for no coverage, 
and ' P' for the $1000 maximum coverage. 
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SPEC: Number for the physician specialty. 
TERMDA TE: Termination date in mmldd/yy format. 
TERMDESC: Termination description which describes the reason for enrollment 
termination. Examples include 'DOCTOR NUMBER CHANGE', ' DECEASED', or 
'GROUP CONSOLIDATION-DIFFERENT BENEFITS ' . 
Thus, there were several observations per patient with a new observation for 
every termination reason. 
The diagnosis data had 544132 diagnoses for the 2229 patients and the 
following variables: 
ID: Unique patient identifier. 
DXDATE: date of diagnosis in mm/dd/yy format. 
ICDl: The ICD-9 code for diagnosis. 
SPEC: Number for the physician specialty. 
For each patient, diagnoses were in many cases repeated with multiple entries at 
different dates. 
The referral data had 55988 referrals for the 2229 patients and the following 
variables: 
ID: Unique patient identifier. 
ADMDATE: Admission date in mm/dd/yy format. 
DCDA TE: Discharge date in mm/dd/yy format. 
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ADMTYPE: Admission type with ' I' for inpatient ,'O' for outpatient, and ' P' for 
professional visits. 
ICDl , ICD2 , and ICD3: Diagnoses codes (ICD-9 diagnoses codes). 
CPTl- -CPT18: Procedure codes. 
For each patient, diagnoses were in many cases repeated with multiple entries at 
different dates. 
The pharmacy data (Rxs data) had 435392 dispensings for the 2229 patients 
and the fo llowing variables: 
ID: Unique patient identifier. 
DRGDA TE: Drug date . 
NDCCODE: NDC drug code 
GENERIC: Generic product identifier. 
DRGNAME: Drug name. 
REFILL: with 'F' for fill and ' R' for refill. 
QUANT: Quantity. 
RXMD: Prescribing physician number. 
NOSCRIPT: Number of scripts. 
There was an observation for each dispensing. 
An excel sheet provided 2 variables: 
RXMD: Prescribing physician number. 
Specialty: Stated the specialty of the physician. 
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Data cleaning and preparation: 
Screening for missing data was carried out using SAS procedures such as 
PROC FREQ and PROC UNIV ARIA TE. A series of checks were conducted to check 
for duplicates and ensure the data was plausible. For example, records in enrollment 
data that had the termination date prior to the effective date were removed. A few 
patients had plantype in the enrollment data as ' P' or 'N' and a termination date prior 
to January 1, 1994, which is the starting date for the drug benefit plan type options. 
These were changed to 'U' for unknown. All datasets were also separately merged 
with the demographic data by the ID to ensure the availability of all patient IDs. 
The next step was to identify patients that had switched from the original drug 
benefit plan option chosen on January 1, 1994. This was carried out using the 
enrollment data, with ' GROUP CONSOLIDATION-DIFFERENT BENEFITS ' for the 
termination description, and a termination date after January 1, 1994. A (0,1) variable 
was created to indicate switching with 1 as switching. A dataset was then created with 
switchers only and duplicates by ID were removed using the NODUPKEY option. 
This was then merged with all other datasets by ID, and switchers were then deleted. 
Among the 325 switchers identified, 251 (77.2%) switched from the full coverage 
plan, with 31 of251 (12.4%) to the no coverage plan, 173 of251 (68.9%) to the partial 
coverage, and 47 of251 (18 .7%) going back to the full coverage plan later in the 
study. Also, 61 (18.8%) of these 325 patients switched from the $1000 maximum 
plan, with 18 of61 (29.5%) to the no coverage, 38of61 (62.3%) to the full coverage, 
and 5of 61 (8.2%) going back to the $1000 maximum coverage later in the study. 
Finally, 13 (4.0%) of the 325 patients switched from the no coverage plan, 8of13 
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(61.5%) to the partial coverage, 4 of 13 (30.8%) to the full coverage, and 1 of 13 
(7.7%) going back to the no coverage later in the study. The final plans chosen by 
these 325 patients were the full coverage plan in 89 patients (27.4%), the $1000 
maximum coverage plan in 186 (57.2%), and the no coverage plan in 50 (15.4%). 
By that, the resulting datasets were for 1904 patients who did not change the 
original plan chosen on January 1, 1994. These datasets were used in all other analyses 
for the 3 manuscripts. 
Manuscript 1 coding and analyses: 
For the first manuscript, the pharmacy data were then used to identify LLA 
prescriptions between July 1, 1995 and June 30, 1996. The first prescription was 
identified. NDC-codes provided by the drug dictionary were used to identify LLAs. 
Separate (0, 1) variables were created to indicate statin, niacin, fibrates, and bile acid 
sequestrant drug use based on NDC codes. 
The pharmacy data were also used to identify LLA prescriptions in the 
previous one year July 1, 1994 - June 30, 1995, and a (0,1) variable was created to 
indicate new or prevalent use of the different LLA classes based on availability of an 
old prescription or not. Thus, (0, 1) variables indicating new statin (snew), new niacin 
(nnew), new fibrate (fnew), and new bile (bnew) were formed. 
Combination therapy was also determined using the pharmacy data. A (0, 1) 
combination variable ( combin) was created, which was 1 if a patient had prescriptions 
for 2 drugs from 2 classes in month 1 and month 2 (between June 1, 1995 and July 30, 
1995) and again in month 3 and 4 (between August 1, 1995 and September 30, 1995). 
A patient was a new user if either of the 2 drugs were new. Combination users were no 
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longer considered monotherpay users (separate datasets for each monotherpay class 
were formed and patients who were combination users were removed and then the 
datasets were stacked again by the SET statement). 
By that, we obtained a dataset with variables, ID, statin, niacin, fibrate, bile 
and combin, and snew, fnew, nnew, and bnew. Variables drgdate and RXMD was also 
kept. 
Demographic data were used to determine the sex and age of these patients 
through merging by ID. Age, calculated from the DOB variable, was converted into 
three age groups: 65-69, 70-74, and above 75. 
Enrollment data were used to obtain plan type chosen for the patients through 
merging by ID. 
To obtain the physician prescriber specialty, the data on the excel sheet was 
imported into SAS and merged by RXMD. Prescriber specialty was categorized into 
internal medicine, cardiologists and others. 
Comorbidities were determined by using both referral and diagnosis data and 
merging by ID. A patient was considered to have CHO if there was a diagnosis (ICD-9 
codes 410-414) in the referral data with ADMDATE prior to DRGDATE, or a 
diagnosis in the diagnosis data with DXDA TE prior to DRGDA TE. A patient was 
considered to have diabetes if there was a diagnosis (ICD-9 codes 250) in the referral 
data with AD MD ATE prior to DRGDA TE, or a diagnosis in the diagnosis data with 
DXDA TE prior to DRGDA TE. A patient was considered to have hypertension if there 
was a diagnosis (ICD-9 codes 401-405) in the referral data with ADMDA TE prior to 
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ORGDATE, or a diagnosis in the diagnosis data with DXDATE prior to DRGDATE. 
Thus, three (0, I) variables were obtained. 
Each drug class was then stratified by the patient characteristics (sex, age 
group, plan type, physician prescriber specialty, CHD, diabetes, and hypertension) by 
PROC FREQ, and cross tabulation. CHISQ was also carried out. This was carried out 
for prevalent and then new users in each of the five classes of drugs. 
Manuscript 2 coding and analyses: 
For the second manuscript, we identified patients with prescriptions of 
LLAs using NDC-codes between July I , 1994 and June 30, 1996. We deleted from 
them patients who had an LLA prescription between July I , 1993 and June 30, 1996. 
The data was then transposed to create a dataset with one record per patient using the 
PROC TRANSPOSE procedure. Patients with first DRGDA TE after January I , 1996 
were deleted. The type of LLA in the first prescription was identified as statin, 
fibrate, bile acid sequestrant, niacin, based on NDC-codes. It was later further 
categorized into a (0, 1) variable indicating statin versus other LLAs. 
Demographic data were used to determine the sex and age of these patients 
through merging by ID. Age, calculated from the DOB variable, was converted into 
two age groups: 70 and above, and below 70. 
Enrollment data were used to obtain plan type chosen for the patients through 
merging by ID. Plan type was further categorized into a (0, 1) variable with full 
coverage as 1 (PLANTYP 'X' ). 
Comorbidities were determined by using both referral and diagnosis data 
through merging by ID. A patient was considered to have been hospitalized for CHD 
177 
if there was a diagnosis (IC0-9 codes 410-414) in the referral data with AO MO A TE 
prior to ORGOATE of the first prescription and AOMTYPE ='I', or a diagnosis in 
the diagnosis data with OXOA TE prior to ORGOA TE of the first prescription. A 
patient was considered to have diabetes if there was a diagnosis (IC0-9 codes 250) in 
the referral data with AO MO A TE prior to ORGOA TE of the first prescription, or a 
diagnosis in the diagnosis data with OXOATE prior to ORGOA TE of the first 
prescription. A patient was considered to have hypertension if there was a diagnosis 
(IC0-9 codes 401-405) in the referral data with AD MO A TE prior to ORGOA TE of 
the first prescription, or a diagnosis in the diagnosis data with OXDA TE prior to 
DRGOATE of the first prescription. Thus, three (0,1) variables were obtained for 
CHO, diabetes, and hypertension. 
To determine the number of other medications prescribed to the patient within 
45 days of the first LLA prescription, pharmacy data were used to determine the other 
medications by removing the prescriptions with NOC-codes of LLAs. This was then 
merged with the previous dataset and a (0, 1) variable was created to indicate a 45 day 
period between the first LLA prescription and the other medications prescription. 
Prescriptions not satisfying the 45-day period were deleted. The remainder were then 
transposed by the PROC TRANSPOSE procedure. An array was formed to determine 
repeated medications based on their NOC-codes. The final number of medications 
was obtained by adding up the columns after converting the NOC-codes to ones. The 
variable was further categorized into 2 categories of three and above or less than 
three. 
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To determine discontinuation, a (0, 1) variable was formed to indicate 
discontinuation if a patient had 180 or more days between any two LLA prescriptions, 
or 180 days or more between the last prescription and end of study period. The latter 
was found by using the PROC SORT procedure to sort the pharmacy data (with new 
LLAs between July 1, 1994 and June 30, 1996) by DESCENDING DRGDATE with 
NODUPKEY option by ID to identify the last LLA prescription and then merging by 
ID. A variable to indicate discontinuation date was formed which was the date of the 
last prescription prior to the 6-months without a prescription+ 180 days. A variable 
indicating time till discontinuation was also created which was the difference between 
the discontinuation date and the date of the first prescription. A (0,1) censorship 
variable was created as well, which was zero for patients that did not discontinue. The 
end of follow up for patients was considered to be the discontinuation date for patients 
that discontinued, or the end of study date for patients that did not discontinue. 
Frequencies obtained by the SAS procedure PROC FREQ. The SAS procedure 
PROC LIFETEST was used to obtain KM plots, log-log KM plots, and the log rank 
statistics. The log-log KM plots were used to test the PH assumption by the graphical 
approach, where the assumption is satisfied unless there is a strong evidence of 
nonparallelism. PROC PHREG was used to fit the stratified Cox PH model with the 
STRATA statement for stratification, and PROC PLOT to obtain adjusted survival 
plots. 
Manuscript 3 coding and analyses: 
For the third manuscript, pharmacy data were used to determine patients 
with a statin prescription between September 1, 1994 and June 30, 1995. Patients with 
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a prescription in the previous year were deleted. The first prescription was used, and 
type of statin in each prescription was determined based on NDC-codes. The statin 
type was further categorized into a (0,1) variable, with one indicating the more 
expensive statins (pravastatin and lovastatin.). 
Demographic data were used to determine the sex and age of these patients 
through merging by ID. Age was calculated from the DOB variable. The linearity of 
the association of age with the dependent variable was examined and age was 
converted into two age groups: 70 and above, and below 70 based on this linearity 
check. 
Enrollment data were used to obtain plan type chosen for the patients through 
merging by ID. Plan type was further categorized into a (0, 1) variable with full 
coverage as 1 (PLANTYP ' X'). 
Comorbidities were determined by using both referral and diagnosis data 
through merging by ID. A patient was considered to have been hospitalized for CHD 
ifthere was a diagnosis (ICD-9 codes 410-414) in the referral data with ADMDATE 
prior to DRGDA TE and ADMTYPE = ' I' , or a diagnosis in the diagnosis data with 
DXDA TE prior to DRGDA TE. A patient was considered to have diabetes if there was 
a diagnosis (ICD-9 codes 250) in the referral data with ADMDA TE prior to 
DRGDATE, or a diagnosis in the diagnosis data with DXDA TE prior to DRGDA TE. 
A patient was considered to have hypertension if there was a diagnosis (ICD-9 codes 
401-405) in the referral data with ADMDATE prior to DRGDATE, or a diagnosis in 
the diagnosis data with DXDA TE prior to DRGDATE. Thus, three (0, 1) variables 
were obtained for CHD, diabetes, and hypertension. 
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To obtain the physician prescriber specialty, we imported the data on the excel 
sheet into SAS and merged by RXMD. Prescriber specialty was categorized into a 
(0, 1) variable with cardiologists coded as 1. 
The SAS procedure PROC FREQ was used to determine various frequencies. 
The SAS procedure PROC LOGISTIC was used for the logistic regression analyses. 
All analyses were performed using SAS for microcomputers version 8.01. 
Writing the SAS programs and interpreting the results were based on fundamentals of 
SAS learned using SAS Programming by Example by Cody and Pass [1 ], and The 
little SAS Book: A Primer by Delwiche and Slaughter [2] , and by studying examples 
presented in Klienbaum's [3] Survival Analysis: A Self Learning Text, and Allison' s 
[4] Logistic Regression Using the SAS System. 
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APPENDIXC. OVERVIEW OF MAJOR FINDINGS 
The objective of the analyses described in manuscript 1 was to assess 
utilization the LLAs during a one-year period among a group Medicare beneficiaries 
enrolled in managed care and with high cholesterol levels. We compared this 
utilization with various patient characteristics including gender, age group, prescriber 
specialty, comorbidities (CHD, diabetes, hypertension), and choice of drug benefit 
plan option. This was carried out for both new and prevalent users during the one-year 
period. 
Statin monotherapy was the most frequently prescribed LLA in both prevalent 
(61 .8%) and new users (65.5%). Combination therapy was the least prescribed 
regimen among both prevalent (1.6%) and new users (0.9%). 
In prevalent LLA use, patients with CHO were more frequently prescribed 
statin monotherapy (p<0.0001) and combination therapy (p=0.0467), but less 
frequently prescribed bile acid sequestrants (p<0.0001) compared to patients without 
CHO. Diabetic patients more frequently used fibrates (p=0.0032), less frequently used 
bile acid sequestrants (p=0.0007) and niacin (p=0.0336), compared to non-diabetics. 
Females were more frequently prescribed bile acid sequestrants compared to males 
(p=0.0213), but this difference no longer existed when the analysis was restricted to 
diabetics or non-diabetics only, indicating a confounding effect of diabetes. 
Cardiologists prescribed fibrates less frequently than internists and other specialties 
(p=0.0092), and patients aged 65-69 were less frequently prescribed a bile acid 
sequestrant compared to other age groups (p=0.0006). 
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In new LLA use, patients with CHD were more frequently prescribed statin 
monotherapy (p=0.0028). Diabetic patients less frequently used bile acid sequestrants 
(p=0.0329) compared to non-diabetics. Females were more frequently prescribed bile 
acid sequestrants compared to males (p=O.O 168), a result that could be confounded by 
diabetes since the result no longer existed when we restricted the analysis to non-
diabetics. The low number of new bile sequestrant users with diabetes prevented us 
from conducting a valid chi-square among diabetics. Finally, internal medicine 
physicians prescribed bile acid sequestrants less frequently than cardiologists and 
other specialties (p=0.0008). 
The type of drug benefit plan chosen was not associated with any of the drug 
regimens prescribed. 
Our results indicate that statins remain the mainstay of hyperlipidemic therapy. 
The very low rate of combination drug use found may, in part, explain why many 
patients on LLAs do not reach their target cholesterol levels, and perhaps help increase 
the use of combination therapy, shown to be safe and effective, in the near future. 
Observed differences in LLA selection in various characteristics could be reflective of 
different lipid levels resulting from comorbidities, mainly CHO and diabetes. Further 
follow-up with lipid levels of patients would give a more definitive explanation to 
these differences. 
The analyses described in manuscript 2 gave insight into the relationship 
between drug benefit plan options for older adults under managed care and persistence 
to lipid-lowering therapy, controlling for potential confounding effects of patient sex, 
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age, co-morbidities (CHD, hypertension or diabetes mellitus), number of medications 
used, and statin use. 
By the end of the study period, 39 .1 % of patients had discontinued their 
medication. The discontinuation increased with time, from 18.3% discontinuing at 6 
months days, to 46.4% at 12 months, and 66.3% at 18 months, with the greatest drop 
occurring in the second half of the first year. 
In the bivariate analysis, a significant difference existed between genders, 
with males having lower discontinuation than females. The discontinuation increased 
from 11. 9% at 6 months, to 39 .8% at 12 months, to 54. 9% at 18 months in males, and 
from 23 % at 6 months, to 50.3% at 12 months, to 73.2% at two years in females 
(p=0.0078). 
A significant difference also existed between those who were hospitalized for 
CHD and those who were not, with CHD patients having lower discontinuation than 
non-CHD patients. The discontinuation increased from 15.7% at 6 months, to 40.9% 
at 12 months, to 59.1% at 18 months in CHD-patients, and from 20.9% at 6 months, to 
51.2% at 12 months, to 72. 7% at 18 months in non-CHO patients (p=0.0424). 
Finally, a significant difference existed between statin users and non-statins 
users, with statin users having lower discontinuation than non-statin users. The 
discontinuation increased from 23.9% at 6 months, to 55.0% at 12 months, to 77.3% at 
18 months in non-statin users, and from 14.4% at 6 months, to 38. 7% at 12 months, to 
56.6% at 18 months in statin users (p=0.0004). 
In the multivariate model , a significant difference in discontinuation existed 
with statin use (HR=0.536; CI=0.375-0.766; p=0.0006), indicating that statin users 
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were less likely to discontinue compared to nonusers. CHD and gender were no longer 
significantly associated with discontinuation. 
The type of drug benefit plan chosen was not significantly associated with the 
discontinuation in the bivariate (p=0.3121) or multivariate model that controls for 
potential confounders (HR=0.877; CI=0.610-1.260; p=0.4 77). Our findings suggest 
that adequate payment mechanisms are not enough to guarantee persistence of lipid-
Jowering therapy. 
The aim of the analysis presented in manuscript 3 was to investigate the 
association between the drug benefit plan type and the type of statin drug prescribed 
(based on relative price) for a group of older adults under managed care, while 
controlling for the potential confounding effects of gender, age, prescriber specialty, 
CHD hospitalization prior to prescription, diabetes diagnosis prior to prescription, 
and hypertension diagnosis prior to prescription. 
Results showed fluvastatin to be the most prescribed statin accounting for 
87.4% of the prescriptions in this patient population. 
The drug benefit plan type was not significantly associated with the type of 
statin prescribed in the bivariate (OR=0.652; CI=0.377-1.126; p=0.1247) or 
multivariate logistic regression model (OR=0.654; CI=0.376-1.139; p=0.1335). 
Other covariates- gender, age, prescriber specialty, CHO hospitalization prior to 
prescription, diabetes diagnosis prior to prescription, and hypertension diagnosis 
prior to prescription- were also not significantly associated with the type of statin 
prescribed. 
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Our results suggest that the drug benefit plan chosen did not affect the choice 
among different statins. Further investigation with initial lipid levels is needed to 
investigate whether the more expensive drugs are being used in patients in need of 
further lowering of LDL-C beyond the capacity of fluvastatin, and whether target 
cholesterol levels are being achieved among all patients to gain the potential benefit of 
these drugs. 
In sum, our results generally indicate that the policy of drug benefit plan 
option initiated at the HMO among older adult members did not significantly 
influence the choice among or persistence of LLAs. 
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APPENDIXD KAPLAN-MEIER SURVIVAL CURVES 
AND LOG-LOG KAPLAN-MEIER SURVIVAL CURVES 
Figure la Kaplan-Meier survival curves for members of the full drug benefit 
plan and members of the $1000 maximum or no drug benefit plan in an elderly 
population of new users of lipid-lowering agents enrolled in a Medicare managed 
care health plan (n=322) 
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Figure lb Log-log Kaplan-Meier survival curves for members of the full drug 
benefit plan and members of the $1000 maximum or no drug benefit plan in an 
elderly population of new users of lipid-lowering agents enrolled in a Medicare 
managed care health plan (n=322) 
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Figure 2a Kaplan-Meier survival curves for males and females in an elderly 
population of new users of lipid-lowering agents enrolled in a Medicare managed 
care health plan (n=322) 
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Figure 2b Log-log Kaplan-Meier survival curves for males and females in an 
elderly population of new users of lipid-lowering agents enrolled in a Medicare 
managed care health plan (n=322) 
o.o 
~ 
Cl 
-0.5 (/) 
CJl 
0 
_J 
-1.0 
.., 
> 
_, 
~ -1.5 
.., 
z: 
CJl 
0 -2.0 
_J 
-2.5 
5.00 
Gender O= females 
Gender I =males 
5 . 25 
STRATA: 
5.50 5.75 6.00 6.25 6.50 6.75 
Log of time 
+--++ gender=O +-+-+ gender= I 
191 
Figure 3a Kaplan-Meier survival curves for ages ~70 and ages < 70 in an elderly 
population of new users of lipid-lowering agents enrolled in a Medicare managed 
care health plan (n=322) 
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Figure 3b Log-log Kaplan-Meier survival curves for ages ~70 and ages < 70 in 
an elderly population of new users of lipid-lowering agents enrolled in a 
Medicare managed care health plan (n=322) 
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Figure 4a Kaplan-Meier survival curves for patients with CHD and patients 
without CHD in an elderly population of new users of lipid-lowering agents 
enrolled in a Medicare managed care health plan (n=322) 
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Figure 4b Log-log Kaplan-Meier survival curves for patients with CHD and 
patients without CHD in an elderly population of new users of lipid-lowering 
agents enrolled in a Medicare managed care health plan (n=322) 
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Figure Sa Kaplan-Meier survival curves for patients with diabetes and patients 
without diabetes in an elderly population of new users of lipid-lowering agents 
enrolled in a Medicare managed care health plan (n=322) 
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Figure Sb Log-log Kaplan-Meier survival curves for patients with diabetes and 
patients without diabetes in an elderly population of new users of lipid-lowering 
agents enrolled in a Medicare managed care health plan (n=322) 
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Figure 6a Kaplan-Meier survival curves for patients with hypertension and 
patients without in an elderly population of new users of lipid-lowering agents 
enrolled in a Medicare managed care health plan (n=322) 
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Figure 6b Log-log Kaplan-Meier survival curves for patients with hypertension 
and patients without hypertension in an elderly population of new users of lipid-
lowering agents enrolled in a Medicare managed care health plan (n=322) 
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Figure 7a Kaplan-Meier survival curves for patients with number of other 
medications ~3 and patients with number of other medications 0-2 in an elderly 
population of new users of lipid-lowering agents enrolled in a Medicare managed 
care health plan (n=322) 
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Figure 7b Log-log Kaplan-Meier survival curves for patients with number of 
other medications :'.'.:3 and patients with number of other medications 0-2 in an 
elderly population of new users of lipid-lowering agents enrolled in a Medicare 
managed care health plan (n=322) 
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Figure 8a Kaplan-Meier survival curves for statin users and nonstatin users in 
an elderly population of new users of lipid-lowering agents enrolled in a 
Medicare managed care health plan (n=322) 
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Figure Sb Log-log Kaplan-Meier survival curves for statin users and non-statin 
users in an elderly population of new users of lipid-lowering agents enrolled in a 
Medicare managed care health plan (n=322) 
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